

# SUBJECT INDEX TO VOLUME 132

- ABCB4**, in intrahepatic cholestasis, testing for, 132:119
- ABCB11**, in intrahepatic cholestasis, testing for, 132:119
- ABCC2 genotype**, and diclofenac hepatotoxicity, 132:272
- Abl**, *Helicobacter pylori* activation of, 132:1309
- Accommodation**, in large bowel, enteric occult reflex and, 132:1912
- Acetaminophen**  
therapeutic doses of, and aminotransferase elevation, 132:1624–ss  
toxicity, mild hypothermia for, 132:3–tmig, 132:372
- 2-Acetylaminofluorene (2-AAF)**, liver regeneration induced by, bone marrow cell differentiation in, 132:1077
- 5-Acetylsalicylic acid (5-ASA)**  
for active ulcerative colitis, 132:1–tmig, 132:66  
and cell cycle progression in colorectal cells, 132:221, 132:1635–c
- Achalasia**, pneumatic dilation *versus* myotomy for, 132:811–ss
- Activator protein-1 (AP-1)**, in *Helicobacter pylori* infection (gerbils), 132:1024
- Activin signaling**, in colorectal cancer, 132:633
- Acute hepatitis**. *See specific virus types*
- Acute pancreatitis**, 132:1127–rev  
AGAI medical position statement on, 132:2019–agai  
AGAI technical review of, 132:2022–agai  
pain in, cannabinoids and, 132:1968
- Adalimumab**, for Crohn's disease, 132:52  
FDA approval of, 132:1644–ghn
- Adaptive immunity**, in hepatitis C, 132:654, 132:667, 132:801–e
- Adefovir**, for hepatitis B, 132:1586–rev
- Adenoma**  
colorectal. *See* Colorectal cancer  
pancreatic. *See* Pancreatic cancer
- Adenosine monophosphate-activated protein kinase**, fuel sensing by, 132:2158
- Adipocyte**, in energy balance and metabolism, 132:2103
- Adipokines**, in nonalcoholic fatty liver disease, 132:2191
- Adiponectin**  
in intestinal inflammation (mice), 132:601, 132:1199–c  
in obesity, 132:2106
- Adipose-derived factors**, 132:2103
- Adipose differentiated-related protein (ADRP)**, actions of, 132:1947
- Adipsin**, in obesity, 132:2109
- Adolescents**, obesity in, 132:2087
- Adults**, obesity in, 132:2087
- Age**, and obesity, 132:2087
- Aging and the Gastrointestinal Tract**, 132:1196–pmr
- Akt**, in colonic epithelial cell survival, 132:587
- Alagille syndrome**, resequencing chip for diagnosis of, 132:119
- Alanine aminotransferase (ALT)**  
acetaminophen therapeutic doses and, 132:1624–ss  
elevated serum levels of, and risk of mortality, 132:475–ghn
- Alcohol**  
and GERD risk, 132:87  
use in hepatitis C, effect on dendritic cell function and NS5 clearance (mice), 132:471–tmig
- Alcohol and the Gastrointestinal Tract**, 132:2076–pmr
- Alcoholic cirrhosis**  
eNOS in, gene and protein expression of, 132:2533  
perforative peritonitis on sclerosing encapsulating peritonitis in, 132:854–ccig, 132:1210–ccig
- Alcoholic hepatitis**  
eNOS in, gene and protein expression of, 132:2533  
gene expression and severity of, 132:687
- Alcoholic liver disease**, *versus* nonalcoholic fatty liver disease, index for, 132:2076–c
- Alcoholic liver disease/nonalcoholic fatty liver disease index (ANI)**, 132:2076–c
- Alcoholic pancreatitis**, ectopic exocytosis in, 132:1527
- Alcohol-induced fatty liver**, complement and, 132:1117
- American Gastroenterological Association (AGA)**  
on computed tomographic colonography, 132:1632–c  
Donowitz's reflection on term as president, 132:1645–ghn  
Hecht elected as vice president of, 132:1646–ghn  
on Medicare reimbursement, 132:474–ghn
- American Gastroenterological Association Institute (AGAI)**  
on acute pancreatitis, 132:2019–agai, 132:2022–agai  
Gastroenterology Core Curriculum of, 132:2012–agai  
on gastrointestinal medication use in pregnancy, 132:824–c  
on gastrointestinal stromal tumors, 132:822–c  
on gender and advancement in gastroenterology, 132:1598–agai  
Julius M. Friedenwald Medal presented to Freston, 132:2580–agai  
LaRusso as new president of, 132:2005–agai, 132:2283–ghn  
late-breaking abstracts submitted to DDW, 132:2585–agai  
report of Obesity Task Force, 132:2272
- Aminotransferases**  
acetaminophen therapeutic doses and, 132:1624–ss  
elevated serum levels of, and risk of mortality, 132:475–ghn
- Amphiregulin deficiency**, and gastric metaplasia (mice), 132:1804, 132:2053–e
- Anal sphincter, internal**, basal tone in, *H-ras* inhibition of RhoA/ROCK and, 132:1401
- Angiopoietin-like peptide 4/fast-ing induced adipose factor**, 132:2109
- Angiotensin II**, and esophageal contractility, 132:249
- Anoikis**, of colonic epithelial cells, cell-cell contact and, 132:587
- Anorectal motility**, *H-ras* inhibition of RhoA/ROCK and, 132:1401
- Antibiotic therapy**, for Crohn's disease, 132:2313, 132:2594–e
- Antigen presentation**, intestinal epithelial exosomes and, 132:1866  
 $\alpha_1$ -Antitrypsin deficiency, resequencing chip for diagnosis of, 132:119

## KEY TO ABBREVIATIONS

agai—American Gastroenterological Association Institute

c—Correspondence

ccig—Clinical Challenges and Images in GI

ce—Comment From the Editors

e—Editorials

ghn—Gastroenterology News

iat—Imaging and Advanced Technology

pmr—Print and Media Reviews

rc—Rapid Communications

rev—Review

ss—Selected Summaries

tmig—This Month in Gastroenterology

- APC inactivation**, chromosomal instability and BUB1B/MAD2L1 up-regulation with, 132:2448
- Apoptosis**  
in alcoholic hepatitis, 132:687  
of colonic epithelial cells, cell-cell contacts and, 132:587  
in colorectal cancer, *XAF1* and, 132:2459  
of hepatocytes, TNF-induced, RelA/p65 and (mice), 132:2489, 132:2601–e  
of intestinal epithelial cells, probiotic solution proteins and, 132:562  
of pancreatic stellate cells, tocotrienol-induced (rat), 132:2518  
radiation-induced, lysophosphatidic acid type 2 receptor and, 132:1834
- Appetite**  
adipose-derived factors and, 132:2103  
gut hormones and, 132:2116
- Aspartate aminotransferase (AST)**, elevated serum levels of, and risk of mortality, 132:475–ghn
- ATF-6**, in endoplasmic stress response, IL-10 and, 132:190
- ATG16L1**, and Crohn's disease, 132:1665, 132:2045–e
- Atherogenic dyslipidemia**, obesity and, 132:2181
- Atoh1 (Math1)**, intestine-specific ablation of, 132:2478
- ATP8B1**, in intrahepatic cholestasis, testing for, 132:119
- Autofluorescence imaging (AFI)**, of Barrett's esophagus, 132:1189–ss, 132:2586–agai
- Autoimmune enteropathy (AIE)**, *FOXP3* gene and, 132:1694
- Autophagy**, of pancreatic stellate cells, tocotrienol-induced (rat), 132:2518
- Autophagy-related 16-like gene (ATG16L1)**, and Crohn's disease, 132:1665, 132:2045–e
- Autosomal recessive polycystic kidney disease (ARPKD)**, octreotide for, 132:1104
- Azithromycin**, for Crohn's disease, 132:2594–e
- Bacteria**  
gut, and obesity, 132:836–ghn  
role in intestinal disorders, 132:481–cc, 132:551, 132:576, 132:797–e, 132:2313, 132:2594–e
- Balloon distention**, in functional dyspepsia, hypersensitivity to, 132:1684
- Ballooning of spleen**, 132:2296–clin, 132:2621–clin
- Bariatric surgery**, 132:462–pmr, 132:2253
- Barium enema**, in Veteran's Affairs patients, 132:4–ghn
- Barium SB follow through (SBFT)**, for small bowel imaging, 132:1651–ccig
- Barrett's esophagus**  
columnar metaplasia in, bone morphogenetic protein 4 and, 132:2412  
endoscopic trimodal imaging in, 132:2586–agai  
high-grade dysplasia in, long-term outcome of treatment, 132:1211–tmig, 132:1226, 132:1607–e  
surveillance and imaging of, 132:1189–ss, 132:2586–agai
- Barrett's Esophagus and Esophageal Adenocarcinoma**, 132:820–pmr
- Barrier function**  
in colonic stress response, 132:1791  
glial-derived  $\gamma$ -nitrosoglutathione and, 132:1344, 132:1615–e  
matrix metalloproteinase 9 and, 132:1877  
myosin light chain kinase and, 132:454–ss  
T-cell LIGHT and, 132:2279–tmig, 132:2383  
toll-like receptor 2 regulation of, 132:1359
- Basal tone**, in internal anal sphincter, *H-ras* inhibition of RhoA/ROCK and, 132:1401
- B cell(s)**, in chronic hepatitis C, 132:801–e
- B-cell lymphomas**, with hepatitis C infection, 132:1205–c
- Behavior therapy**, for obesity, 132:2226
- Beta-thalassemics**, hepatitis C virus clearance in, 132:1634–c
- Biliary epithelial cell antibodies (BEC-Ab)**, in primary sclerosing cholangitis, 132:1504
- Biliopancreatic diversion**, 132:2253
- Biographical Sketch**  
Brunner, Johann Conrad, 2284  
Kelly, Howard Atwood, 132:10  
Luschka, Hubert von, 132:1216  
Ormond, John Kelso, 132:838  
Saint, Charles F. M., 132:476  
Whipple, Allen Oldfather, 132:1654
- Body fat**, and colorectal cancer, 132:816–ss
- Body mass index (BMI)**  
and GERD risk, 132:87  
in overweight and obesity definitions, 132:2087
- Bone marrow cells**  
differentiation in 2-AAF/PHx-induced liver regeneration, 132:1077  
inducible nitric oxide synthase derived from, in colitis, 132:1778
- Bone marrow colitogenic CD4<sup>+</sup> T cells**, 132:176
- Bone morphogenetic protein 4**, and columnar metaplasia in Barrett's esophagus, 132:2412
- Bowel urgency**, in irritable bowel syndrome, 132:38
- Brain-gut axis alterations**, in postinfective visceral chemosensitivity, 132:1375
- Brunner, Johann Conrad**, x–bio
- BUB1B/MAD2L1 up-regulation**, in APC-related chromosomal instability, 132:2448
- Buserelin**, and chronic intestinal pseudo-obstruction, 132:45
- Butyrate**, and intestinal sodium absorption, 132:236
- C3**, and alcohol-induced fatty liver, 132:1117
- C5**, and alcohol-induced fatty liver, 132:1117
- Calcium**, interstitial cells of Cajal handling of, 132:1852, 132:2057–e
- Calcium channels**, L-type, vasoactive intestinal peptide and, 132:1212–tmig, 132:1388
- cAMP responsive element binding protein (CREB)**  
in *Helicobacter pylori* infection (gerbils), 132:1024  
vasoactive intestinal peptide and, 132:1212–tmig, 132:1388
- Campylobacter jejuni**, and irritable bowel disease, 132:481–cc
- Cancer**. *See also specific types*  
methylation and, 132:2069–ss  
obesity and related disorders and, 132:2208
- Cancer stem cells (CSCs)**, 132:2542
- Cannabinoids**, and pain in acute pancreatitis, 132:1968
- Capillary hemangioma of small intestine**, 132:1656–clin, 132:2084–clin
- Capsule endoscopy**, PillCam COLON, 132:2586–agai
- Capsule enteroscopy**  
*versus* push, in obscure intestinal bleeding, 132:831–tmig, 132:855  
of small bowel, 132:1651–ccig
- Carbachol**, pancreatic exocytosis induced by, 132:1527
- CARD8 gene**, in inflammatory bowel disease, lack of association found, 132:2078–c, 132:2080–c

- CARD15 (NOD2) gene**, in Crohn's disease, 132:481–cc, 132:576, 132:1665, 132:2045–e
- β-Catenin**  
in colonic epithelial cell survival, 132:587  
in colorectal cancer, targeting of, 132:208  
sporadic activation of, precancerous lesions with, 132:1299  
in taste bud development, 132:2071–ss
- β-Catenin/TCF4 complex**, splicing factor-1 and, 132:1039
- CCL5-CCR5 chemokine network**, and FOXP3<sup>+</sup> T cell migration in colitis, 132:966
- CD133**  
cancer stem cells expressing, 132:2542  
pancreatic ductal progenitor cells expressing, 132:720
- CD40-CD40 ligand**, in colitis, 132:955
- CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells**, in hepatocellular carcinoma, 132:2328
- CD4<sup>+</sup>NKG2D<sup>+</sup> T cells**, in Crohn's disease, 132:2346
- CD4<sup>+</sup> T cells**  
colitogenic, 132:176  
in hepatitis C  
acute, 132:654  
chronic, 132:667, 132:801–e  
vaccine-induced responses of, 132:1626–ss
- CD8<sup>+</sup> T cells**  
in hepatitis C  
acute, 132:654  
alcohol use and, 132:698  
chronic, 132:667, 132:801–e  
vaccine-induced responses of, 132:1626–ss  
in hepatocellular carcinoma, regulatory T cells and, 132:2328
- Cecal intubation**, in colonoscopy, 132:2277–tmig, 132:2297
- Celiac disease**  
chemokine receptor 9 reduction in, 132:2371  
endomysial antibody (EMA) positivity in, 132:2585–agai  
IL-15 inhibition of TGF-β in, 132:994, 132:1174–e  
tissue transglutaminase and epithelial cell proliferation in, 132:1245
- Cell cycle**, in colorectal cells, 5–ASA and progression of, 132:221, 132:1635–c
- Cell scattering**, in *Helicobacter pylori* infection, 132:1309
- Cellular homeostasis**, *Math1* and, 132:2478
- Center for Drug Evaluation and Research (CDER)**, 132:1644–ghn
- Central nervous system**  
fuel sensing in, and energy balance, 132:2158  
reorganization, and chronic pancreatitis pain, 132:1546, 132:1618–e
- Cerebral blood flow**, regional, during gastric distention, in functional dyspepsia, 132:1684
- Ceruloplasmin**, as modifier of hemo-chromatosis (mice), 132:679
- Challenges in Colorectal Cancer**, 132:1629–pmr
- Challenges in Inflammatory Bowel Diseases**, 132:2075–pmr
- CHARM Trial**, 132:52
- Chemokine network**, and FOXP3<sup>+</sup> T cell migration in colitis, 132:966
- Chemokine receptor 9**, in celiac disease, reduction of, 132:2371
- Chemotherapy**, evidence-based, in colorectal cancer, 132:1630–pmr
- Children**  
hepatitis B virus in, viremia and HBeAg seroconversion in, 132:2340  
obesity in, 132:2087
- Chloride channels**, in cholera, lectin-based inhibitors of, 132:1234
- Cholangiocarcinoma**  
SOCS-3 silencing in, 132:384  
sodium iodide symporter in, 132:1495
- Cholangiocyte(s)**, proliferating, 132:415–srr
- Cholangiocyte adenosine 3',5'-cyclic monophosphate**, octreotide and, 132:1104
- Cholecystokinin**, and appetite, 132:2116
- Cholera**, lectin-based CFTR inhibitors for, 132:1234
- Cholestasis**  
inherited intrahepatic, resequencing chip for diagnosis of, 132:119  
parenteral nutrition-associated, in pre-term neonates, oral erythromycin and decrease in, 132:1726
- Cholesterol levels**, in obesity, 132:2181
- Chromoscopy-guided endomicroscopy**, in ulcerative colitis, 132:874
- Chromosomal instability**  
APC inactivation and, 132:2448  
in colorectal cancer, 132:127, 132:551, 132:2448  
*Enterococcus faecalis* and, 132:551
- Chronic colitis**, bone marrow CD4<sup>+</sup> T cells in, 132:176
- Chronic hepatitis**. *See specific virus types*
- Chronic intestinal pseudo-obstruction (CIPO)**, busserelin and, 132:45
- Chronic pancreatitis (CP)**, 132:1557–rev  
imaging of, 132:484–ccig  
pain in, cortical reorganization and, 132:1546, 132:1618–e  
tocotrienol-induced stellate cell death in (rat), 132:2518
- CIMP (CpG island methylator phenotype)**, in colorectal cancer, 132:127, 132:1184–ss
- CIPO (chronic intestinal pseudo-obstruction)**, busserelin and, 132:45
- Cirrhosis**  
alcoholic  
eNOS in, gene and protein expression of, 132:2533  
perforative peritonitis on sclerosing encapsulating peritonitis in, 132:854–ccig, 132:1210–ccig  
surgical risk in, 132:1211–tmig, 132:1261, 132:1609–e
- c-jun**, FHL2 suppression and, 132:1066
- Clarithromycin**, for Crohn's disease, in two-year combination therapy, 132:2313, 132:2594–e
- Clinical Challenges and Images in GI**  
benign schwannoma of pancreatic head, 132:489, 132:830  
capillary hemangioma of small intestine, 132:1656, 132:2084  
*Fasciola hepatica* infection, 132:15, 132:467  
microvillous inclusion disease, 132:1225, 132:1639  
oral lichenoid reaction in Crohn's disease, 132:488, 132:829  
perforated diverticulum with neck abscess, 132:1655, 132:2083  
rectal carcinoid tumor, 132:853, 132:1209  
solid pseudopapillary tumor of pancreas, 132:1224, 132:1638  
splenic infarction, total, due to torsion, 132:2296, 132:2621  
Von Hippel-Lindau disease type I, 132:16, 132:468
- Clinical Dilemmas in Inflammatory Bowel Disease**, 132:820–pmr
- Clinical trials**, in ulcerative colitis, activity indices and efficacy end points for, 132:763–srr
- Clofazimine**, for Crohn's disease, in two-year combination therapy, 132:2313, 132:2594–e

**Cloned animals**, food from, FDA risk assessment of, 132:835–ghn

***Clostridium difficile* toxin A enteritis**, PAR<sub>2</sub>, DPPI, trypsin, and trypsin in, 132:2422, 132:2599–e

**c-Met**, pancreatic ductal progenitor cells expressing, 132:720

## Coffee

and GERD risk, 132:87

and liver cancer risk, 132:1740

**Colectomy rate**, in ulcerative colitis, European, 132:507

**Colitis**. *See also* specific types

adiponectin in (mice), 132:601, 132:1199–c

bone marrow-derived inducible nitric oxide synthase in, 132:1778

CD40-CD40 ligand in, 132:955

FOXP3<sup>+</sup> T cells in, migration of, 132:966

helminth infection and (mice), 132:1320

IL-23 in, monoclonal antibodies to IL-23 and, 132:2278–tmig, 132:2359

macrophage migration inhibitor factor in, sex steroids and (rat), 132:982

matrix metalloproteinase 9 in, 132:1877

R-spondin1 and (mice), 132:1331

**Colonic epithelial cells**, anoikis of, cell-cell contact and, 132:587

**Colonic hypersensitivity**, in irritable bowel syndrome, 132:464–c, 132:470–tmig, 132:615

**Colonic motility**, vasoactive intestinal peptide and, 132:1212–tmig, 132:1388

**Colonic stress response**, PPAR $\gamma$  and, 132:1791

**Colonography**, computed tomographic, AGA position statement on, 132:1632–c

## Colonoscopy

conventional *versus* virtual, 132:809–ss improvement of, technology *versus* technique in, 132:1221–ccig

incomplete, 132:2277–tmig, 132:2297, 132:2588–e

new or missed colorectal cancers after, 132:96

screening

*versus* FOBT and flexible sigmoidoscopy, 132:2277–tmig, 132:2304, 132:2591–e

*versus* PillCam COLON capsule endoscopy, 132:2586–agai

recommendations based on gender, 132:2605–ss

in Veteran's Affairs patients, 132:4–ghn

withdrawal times and detection in, 132:2065–ss

## Colorectal cancer

APC inactivation in, 132:2448

bacteria/microbes and, 132:481–cc, 132:551, 132:797–e

body fat and, 132:816–ss

cell cycle progression in, 5–ASA and, 132:221, 132:1635–c

challenges in, 132:1629–pmr

CpG island methylator phenotype (CIMP) in, 132:127, 132:1184–ss

DNA hypermethylation of *MAL* in, 132:1631–c

*Elf-3* deficiency and TGF- $\beta$ RII rescue in (mice), 132:1410

evidence-based chemotherapy strategies in, 132:1630–pmr

FHL2 suppression and, 132:1066

Forkhead Box M1 transcription factor in (mice), 132:1420

genome of, large-scale sequencing of, 132:1186–ss

growth differentiation factor-15 in, 132:1204–c

homozygous *PMS2* deletion and, 132:527

improving detection of, technology *versus* technique in, 132:1221–ccig

invasive, identifying new biomarkers in, 132:823–c

new or missed, after colonoscopy, 132:96

nonsteroidal anti-inflammatory drug-activated gene in, 132:1204–c

obesity and related metabolic disturbances and, 132:2208

physical activity and survival in, 132:456–ss

reciprocal targeting of *Hath1* and  $\beta$ -catenin in, 132:208

rofecoxib for chemoprevention in, peptic ulcer and bleeding events with, 132:490

screening

comparison of methods for, 132:2277–tmig, 132:2304, 132:2591–e

incomplete colonoscopy in, 132:2277–tmig, 132:2297

PillCam COLON capsule endoscopy for, 132:2586–agai

in primary care, 132:2591–e

recommendations based on gender, 132:2605–ss

in Veteran's Affairs patients, 132:4–ghn

somatic quantitative genetic alterations in, detection of, 132:645

sporadic, as infectious disease, 132:797–e

T-cell factor (TCF) in, 132:628

whole-body scans for diagnosis of, 132:473–ghn

Wnt signaling system in, 132:208, 132:628

*XAF1* alteration in, 132:2459

## Colorectal Cancer: Evidence-Based Chemotherapy Strategies

132:1630–pmr

## Colorectal polyps

identifying new biomarkers for, 132:823–c

improving detection of, technology *versus* technique in, 132:1221–ccig

PillCam COLON capsule endoscopy for, 132:2586–agai

**Columnar metaplasia**, in Barrett's esophagus, bone morphogenetic protein 4 and, 132:2412

## Comment from the Editors

In the Beginning Was *Helicobacter pylori*: Roles for Microbes in Other Intestinal Disorders, 132:481

Enteric Neuroscience: the Dawn of a New Discipline, 132:1217

HuGE Reviews and Meta-analysis of Gene Association Studies, 132:839

The NIH, Research Institutions and Industry: Working Together on a Shared Goal, 132:1647

Preclinical Evaluation of Therapeutic Strategies for Gastrointestinal Cancers, 132:2285

Translational Research: The Study of Community Effectiveness in Digestive and Liver Disorders, 132:8

**Community effectiveness**, 132:8–ce

**Complement**, and alcohol-induced fatty liver, 132:1117

**Complementary and alternative medicine**, for chronic hepatitis C, 132:1925

**Computed tomographic colonography**, AGA position statement on, 132:1632–c

**Computed tomographic enterography (CTE)**, of small bowel, 132:1651–ccig

**Computed tomography (CT)**, 132:11–ccig

of small bowel, 132:1651–ccig

whole-body, for colorectal cancer diagnosis, 132:473–ghn

**Conflicts of interest**, 132:841

**Connexin 43**, in necrotizing enterocolitis, interferon- $\gamma$  and, 132:2395

**Considering Weight-Loss Surgery: The Facts to Know for a Healthy Recovery**, 132:462–pmr

**Constipation**, irritable bowel syndrome with

lubiprostone for, 132:2586–agai

tegaserod for, 132:397–rev

withdrawal from market, 132:2287–p



**Continuing Medical Education**

**(CME) Activities**, 132:432,  
132:787, 132:1164, 132:1595,  
132:1999, 132:2577

**Coronary heart disease**, obesity and,  
132:2181

**Correspondence**

AGAI Technical Review Statements Regarding GIST Are Troubling,  
132:822

AGA Position Statement of Computed Tomographic Colonography, 132:1632

American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medication in Pregnancy,  
132:824

B-Cell Lymphomas Associated With HCV Infection, 132:1205

Combined Evidence from Three Large British Association Studies Rejects *TUCAN/CARD8* as an IBD Susceptibility Gene, 132:2078

Distinguishing Nonalcoholic Fatty Liver Disease from Alcoholic Liver Disease: Is ANI Enough?, 132:2076

DNA Hypermethylation of *MAL: A* Promising Biomarker for Colorectal Tumors, 132:1631

HCV Clearance Among Hemophiliacs and Beta-Thalassemics, 132:1634

*Helicobacter pylori* and Gastric Cancer: Neither Friend or Foe, 132:2076

Hepatitis B Surface Antigen Clearance in Lamivudine-Treated Patients: Main Therapeutic Goal?, 132:2617

Identifying New Biomarkers Associated With Invasive Colorectal Cancer and Colorectal Polyps, 132:823

NAG-1/GDF-15: No Evidence for an Inhibitory Role in Colon Cancer, 132:1204

No Association Between the *TUCAN-(CARD8)* Cys10Stop Mutation and Inflammatory Bowel Disease in a Large Retrospective German and a Clinically Well-Characterized Norwegian Sample, 132:2080

PIN1 Promoter Polymorphisms in Hepatocellular Carcinoma Patients, 132:2618

The Role of Adiponectin in Colitis, 132:1199

Systematic Review of HVPG Measurement: Statistics Versus Clinical Applicability, 132:1201

Visceral Hypersensitivity in Irritable Bowel Syndrome: Does It Really Normalize Over Time?, 132:464

**Cortical reorganization**, and chronic pancreatitis pain, 132:1546, 132:1618–e

**Corticosteroids**, adipose production of,  
132:2110

**Costa, Robert H.**, 132:1432

**cox-2**, FHL2 suppression and, 132:1066

**CpG island methylator phenotype (CIMP)**

in colorectal cancer, 132:127,

132:1184–ss

and ulcerative colitis-associated neoplasias, 132:1254

**Crohn's disease**

active, natalizumab for, 132:1641–tmig,  
132:1672

adalimumab for, 132:52

FDA approval of, 132:1644–ghn

antibiotic therapy for, two-year combination, 132:2313, 132:2594–e

antibody response in, 132:576

bacteria/microbes and, 132:481–ce, 132:576, 132:2313, 132:2594–e

CD4<sup>+</sup>NKG2D<sup>+</sup> T cells in, 132:2346

genome-wide association studies of, 132:2045–e

ileal, *ATG16L1* and, 132:1665, 132:2045–e

IL-23 receptor gene in, 132:5ghn, 132:481–ccig, 132:1641–tmig, 132:1657, 132:2045–e

impotent immune system in,  
132:2609–ss

independence of genes in, 132:1665,  
132:2045–e

infliximab for  
oral lichenoid reaction to, 132:488–clin, 132:829–clin

in pediatric patients, 132:831–tmig,  
132:863, 132:1167–e

*NOD2 (CARD15)* gene in, 132:481–ccig, 132:576, 132:1665, 132:2045–e

*TUCAN/CARD8* in, lack of association found, 132:2078–c, 132:2080–c

**Cross-sectional imaging**, 132:11–ccig

**CUGBP2**, inhibition of HuR in COX-2 mRNA translation, 132:1055

**CX3CR1+ T cells**, in inflammatory bowel disease, fractalkine recruitment of, 132:139

**Cyclooxygenase-2 (COX-2)**

in colonic stress response, 132:1791

mRNA translation of, CUGBP2 inhibition of HuR in, 132:1055

**Cyclooxygenase inhibitor**, nitric oxide-releasing and portal hypertension (rat), 132:709

**Cyclooxygenase-2 inhibitors (COXIBs)**

gastrointestinal complications of, 132:469–tmig, 132:490, 132:498, 132:790–e

promise of and controversy over, 132:790–e

**CYP2C8 genotype**, and diclofenac hepatotoxicity, 132:272

**Cystic fibrosis transmembrane conductance regulator (CFTR)**, in cholera, lectin-based inhibitors of, 132:1234

**Cytochrome p450 2E1**, in alcoholic hepatitis, 132:687

**Cytokines**. *See also* specific types

in alcoholic hepatitis, 132:687

in appetite and obesity, 132:2109

in GERD-associated esophageal dysmotility, 132:154

in hepatitis C, Silymarin and, 132:1925

in irritable bowel syndrome, 132:913

in nonalcoholic fatty liver disease, 132:2191

in primary sclerosing cholangitis, 132:1504

**Cytotoxin-associated gene A**

**(CagA)**, in *Helicobacter pylori*

infection, 132:1309, 132:1642–tmig

**Decay-accelerating factor**, and alcohol-induced fatty liver, 132:1117

**Dendritic cells**, antigen presentation by, intestinal epithelial exosomes and, 132:1866

**Dendritic function**, in hepatitis C, alcohol and (mice), 132:471–tmig, 132:698

**Depression**, interferon-induced in hepatitis C, serotonin 1-A receptor gene as predictor of, 132:1279

**Diabetes mellitus**, type 2

and colorectal cancer, 132:2208

incretins in, 132:2131

obesity-induced inflammation and, 132:2169

and pancreatic cancer, 132:2208

prevention of, 132:2226

and prostate cancer, 132:2208

**Diclofenac**

hepatotoxicity of, genetic susceptibility to, 132:272

hydrogen-sulfide releasing, 132:2–tmig, 132:261

**Diet**

for obesity, 132:2226

and pancreatic cancer risk, 132:113, 132:441–e

- Digestive Disease Week**, late-breaking abstracts presented at, 132:2585–agai
- Digestive Endoscopy in the Second Millennium: From the Lichtleiter to Echoendoscopy**, 132:462–pmr
- Dipeptidyl peptidase I (DPPi)**, in *Clostridium difficile* toxin A enteritis, 132:2422, 132:2599–e
- Direct visualization**, 132:11–ccig
- Disclosures**, of conflicts of interest, 132:841–jp
- Diverticulum**, perforated, with neck abscess, 132:1655–clin, 132:2083–clin
- DNA hypermethylation of MAL**, in colorectal cancer, 132:1631–c
- DNA methylation**, in cancer, 132:2069–ss
- DNA methyltransferase (DNMT)**, in hepatocellular carcinoma, hepatitis B X-protein and, 132:1476
- Donowitz, Mark**, 132:1645–ghn
- Double balloon enteroscopy (DBE)**, of small bowel, 132:1651–ccig
- Drug development**  
for functional and motility disorders, 132:2287–p  
preclinical evaluation in, 132:2285–ccig  
serotonin signaling system and, 132:397–rev
- Drug-induced liver injury (DILI)**, chronic liver disease from, 132:2067–ss
- Drug resistance**, in chronic hepatitis B, 132:1574–rev
- Drug safety**, FDA reinforcement of commitment to, 132:1644–ghn
- Ductal epithelium**, pancreatic progenitor cells of, 132:720
- Duodenal switching**, biliopancreatic diversion with, 132:2253
- Duodenal T cells**, in celiac disease, chemokine receptor 9 and, 132:2371
- Duodenal ulcers**, time trends in mortality, 132:2320
- Dysentery**, irritable bowel syndrome after, 132:458–ss
- Dyslipidemia**, atherogenic, obesity and, 132:2181
- Dyspepsia**, functional, hypersensitivity to balloon distention in, 132:1684
- Dysphagia**, flexible endoscopic evaluation of, 132:461–pmr
- Dysplasia**, high-grade, in Barrett's esophagus endoscopic trimodal imaging of, 132:2586–agai  
long-term outcome of treatment, 132:1211–tmig, 132:1226, 132:1607–e
- Eating disorders**, management of, 132:2075–pmr
- Echoendoscopy**, 132:462–pmr
- Ectopic exocytosis**, in alcohol pancreatitis, 132:1527
- Editorials**  
Antimycobacterial Therapy in Crohn's Disease: Game Over, 132:2594  
Bone Marrow Stem-Cell Mediated Regeneration in IBD: Where Do We Go From Here?, 132:1171  
Ca<sup>2+</sup> Handling in Human Interstitial Cells of Cajal, 132:2057  
Colonoscopy: A Tarnished Gold Standard?, 132:2588  
Colorectal Cancer Screening in Primary Care, 132:2591  
Endoscopic Therapy for Barrett's High-Grade Dysplasia: Entering the Therapeutic Arena, 132:1607  
Genome-Wide Association Studies Herald a New Era of Rapid Discoveries in Inflammatory Bowel Disease Research, 132:2045  
Got Guts? Need Nerves!, 132:1615  
Hepatic Stellate Cells: The Only Cells Involved in Liver Fibrogenesis? A Dogma Challenged, 132:2059  
Hepatitis B X-protein and PIN1 in Liver Cancer: "Les Liaisons Dangereuses," 132:1180  
Hepcidin Activation During Inflammation: Make It STAT, 132:447  
Hog Heaven on the Road to Liver Cell Therapy, 132:450  
Insulin Resistance: Cause or Consequence of Nonalcoholic Steatohepatitis?, 132:444  
Intracellular *Helicobacter pylori* and Gastric Carcinogenesis: An "Old" Frontier Worth Revisiting, 132:1177  
It's Chickens and Eggs All Over Again: Is Central Reorganization the Result or Cause of Persistent Visceral Pain?, 132:1618  
Metaplasia as a Premalignant Pathology in the Stomach, 132:2053  
Methionine Intake and Pancreatic Cancer Risk: Digesting the Evidence, 132:441  
Mucosal Inflammation in Celiac Disease: Interleukin-15 Meets Transforming Growth Factor  $\beta$ -1, 132:1174  
Nuclear Factor- $\kappa$ B in the Liver: Friend or Foe?, 132:2601  
Penetration of Hemochromatosis: Mice to the Rescue, 132:805  
Predicting Surgical Risk in Patients with Cirrhosis: From Art to Science, 132:1609  
Protease-Activated Receptor 2 in the Intestinal Inflammation Response Induced by *Clostridium difficile* Toxin A, 132:2599  
Ribavirin: Is It a Mutagen for Hepatitis C Virus?, 132:2050  
Searching for the Answer to Irritable Bowel Syndrome in the Colonic Mucosa: SERTainty and UnSERTainty, 132:437  
Selective COX-2 Inhibitors: A Promise Unfulfilled?, 132:790  
Sporadic Colorectal Cancer: An Infectious Disease?, 132:797  
Sweet Clarity: Less Invasive Measures of Hepatic Glucose Metabolism, 132:794  
T and B cells in Hepatitis C Virus Control: What They Do and When They Fail, 132:801  
Timing Infliximab Therapy in Pediatric Crohn's Disease, 132:1167  
Treatment of Hepatitis C: Don't Put All Your Eggs in One Basket!, 132:1611
- Education**, and GERD risk, 132:87
- Efficacy of Natalizumab in Crohn's disease Response and Remission (ENCORE) trial**, 132:1641–tmig, 132:1672
- Elf-3** deficiency, TGF- $\beta$ RII rescue in (mice), 132:1410
- ENCORE trial**, 132:1641–tmig, 132:1672
- Endocannabinoid system**, in acute pancreatitis, 132:1968
- Endocrine tumors**, malignant digestive, survival from, 132:899
- Endomicroscopy**, chromoscopy-guided, in ulcerative colitis, 132:874
- Endomysial antibody (EMA) positivity**, in celiac disease, 132:2585–agai
- Endoplasmic stress response**, IL-10 and, 132:190
- Endoscopic mucosal resection (EMR)**, 132:848–ccig
- Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management**, 132:2614
- Endoscopic retrograde cholangiography (ERCP)**, 132:484–ccig
- Endoscopic retrograde pancreatography (ERP)**, 132:484–ccig

- Endoscopic submucosal dissection (ESD)**, 132:848–ccig
- Endoscopic surgery**, intraluminal, 132:848–ccig
- Endoscopic trimodal imaging**, in Barrett's esophagus, 132:2586–agai
- Endoscopic ultrasound (EUS)**, of pancreas, 132:484–ccig
- Endoscopy**. *See also* specific types  
digestive, history of, 132:462  
flexible, for swallowing evaluation, 132:461–pmr
- Endothelial nitric oxide synthase (eNOS)**, in alcoholic hepatitis, gene and protein expression of, 132:2533
- Energy balance**  
adipocyte in, 132:2103  
CNS fuel sensing in, 132:2158  
gut hormones and, 132:2116
- England**, survival from malignant digestive endocrine tumors in, 132:899
- Entecavir**, for hepatitis B, 132:1586–rev
- Enteric neuroscience**, 132:1217–ccig
- Enteric occult reflex**, and large bowel transit, 132:1912
- Enteritis**, *Clostridium difficile* toxin A, PAR<sub>2</sub>, DPPI, trypsin, and trypsin in, 132:2422, 132:2599–e
- Enterochromaffin cells**, serotonin release from  
in neonatal intestine (guinea pig), 132:2438  
odorant stimulation and, 132:1643–tmig, 132:1890
- Enterococcus faecalis**  
and chromosomal instability in mammalian cells, 132:551  
and colorectal cancer, 132:481–ccig, 132:551, 132:797–e
- Enterocolitis**, necrotizing, interferon- $\gamma$  inhibition of enterocyte migration in, 132:2395
- Enterocyte migration**, in necrotizing enterocolitis, interferon- $\gamma$  inhibition of, 132:2395
- Enteropathy-type T-cell lymphoma**, whole-genome analysis and HLA genotyping of, 132:1902
- Enteroscopy**  
push *versus* capsule, in obscure intestinal bleeding, 132:831–tmig, 132:855  
of small bowel, 132:1651–ccig
- Eosinophilic esophagitis**, mepolizumab for, 132:2586–agai
- Epidermal growth factor receptor (EGFR) ligands**, in gastric metaplasia (mice), 132:1804, 132:2053–e
- Epithelial activation**, in celiac disease, 132:2371
- Epithelial cells**  
biliary, antibodies to, in primary sclerosing cholangitis, 132:1504  
colonic, anoikis of, cell-cell contact and, 132:587  
intestinal  
in celiac disease, tissue transglutaminase and, 132:1245  
in Crohn's disease, MICA-NKG2D interactions and, 132:2346  
differentiation of, matrix metalloproteinase 9 and, 132:1877  
in *Elf-3* deficiency, TGF- $\beta$ RII rescue of (mice), 132:1410  
growth and survival of, probiotic soluble proteins and, 132:562  
IL-10 and endoplasmic stress response in, 132:190  
IL-21 and MIP-3 $\alpha$  synthesis by, 132:166  
releasing antigen-presenting vesicles, 132:1866  
Wnt/TCF signature in, 132:628
- Epithelial sodium channel (ENaC)**, butyrate and, 132:236
- Erythromycin**, oral, and decrease in parenteral nutrition-associated cholestasis in preterm neonates, 132:1726
- Escherichia coli**  
and colorectal cancer, 132:481–ccig  
and irritable bowel disease, 132:481–ccig
- Esomeprazole**, comparison with other proton pump inhibitors, 132:1622–ss
- Esophageal adenocarcinoma**, Barrett's esophagus and, 132:820–pmr
- Esophageal contractility**, angiotensin II and, 132:249
- Esophageal motility**, in achalasia, treatment of, 132:811–ss
- Esophageal peristalsis**, development in neonates, 132:1718
- Esophageal sphincter relaxation**, transient lower, obesity and, 132:883
- Esophagectomy**, for Barrett's esophagus, *versus* photodynamic therapy, 132:1211–tmig, 132:1226, 132:1607–e
- Esophagitis**  
columnar metaplasia in, bone morphogenetic protein 4 and, 132:2412  
eosinophilic, mepolizumab for, 132:2586–agai  
GERD-associated, cytokines and dysmotility in, 132:154
- Estrogen**, and macrophage migration inhibitory factor, in colitis (rat), 132:982
- Ethanol**. *See* Alcohol
- Europe**  
colectomy rate for ulcerative colitis in, 132:507  
time trends in ulcer mortality in, 132:2320
- European Association for the Study of the Liver (EASL)**, hepatitis C reports to  
on long-term follow-up and criteria of cure, 132:2281–ghn  
on telaprevir, 132:2282–ghn
- Evidence-based chemotherapy**, in colorectal cancer, 132:1630–pmr
- Exosomes**, intestinal epithelial, function of, 132:1866
- Extracellular matrix proteins**, in alcoholic hepatitis, 132:687
- Extracellular signal-regulated kinase (ERK) 1/2**, in primary sclerosing cholangitis, 132:1504
- Familial adenomatous polyposis**, APC inactivation in, 132:2448
- Fasciola hepatica** infection, 132:15–clin, 132:467–clin
- Fatty liver disease**  
adipose differentiation-related protein and, 132:1947  
alcoholic, complement and, 132:1117  
hepatitis B X-protein and, 132:1955  
nonalcoholic  
adipose differentiation-related protein in, 132:1947  
*versus* alcoholic liver disease, index for, 132:2076–c  
epidemiology of, 132:2191  
FoxO1 and stellate cell activation in, 132:1434  
obesity and  
inflammation in, 132:2169  
lipid and glucose metabolism in, 132:2191
- FDA**. *See* Food and Drug Administration
- Fecal occult blood testing (FOBT)**  
*versus* colonoscopy and flexible sigmoidoscopy, 132:2277–tmig, 132:2304, 132:2591–e  
in Veteran's Affairs patients, 132:4–ghn

**FESST - Flexible Endoscopic Evaluation of Swallowing With Sensory Testing**, 132:461–pmr

**FHL2 suppression**, and gastrointestinal carcinogenesis, 132:1066

**Flexible sigmoidoscopy**

*versus* colonoscopy and FOBT, 132:2277–tmig, 132:2304, 132:2591–e

in Veteran's Affairs patients, 132:4–ghn

**Flow cytometric cell sorting**, of pancreatic ductal progenitor cells, 132:720

**<sup>18</sup>Fluorodeoxyglucose (FDG) PET**, 132:11–ccig

quantification of liver glucose metabolism by, 132:531, 132:794–e

**Food**, from cloned animals, FDA risk assessment of, 132:835–ghn

**Food allergy**, in IPEX syndrome variant, 132:1705

**Food and Drug Administration (FDA)**

adalimumab (Humira) approval by, 132:1644–ghn

HepaGam B approval by, 132:2281–ghn  
reinforcement of safety commitment by, 132:1644–ghn

risk assessment of food from cloned animals, 132:835–ghn

**Forkhead Box M1 transcription factor (Foxm1)**, in colorectal cancer (mice), 132:1420

**Forkhead transcription factor**

**FoxO1**, in liver fibrogenesis, 132:1434

**FOXP3 gene**

and autoimmune enteropathy, 132:1694  
and hepatocellular carcinoma, 132:2328  
and IPEX syndrome, 132:1694, 132:1705

**FOXP3<sup>+</sup> T cells**, migration in colitis, chemokine network and, 132:966

**Fractalkine**, in inflammatory bowel disease, 132:139

**Freston, James W.**, 132:2580–agai

**Fuel sensing**, CNS, 132:2158

**Functional and motility disorders (FMDs)**, tegaserod for, withdrawal from market, 132:2287–p

**Functional dyspepsia (FD)**, hypersensitivity to balloon distention in, 132:1684

**The Future of Drug Safety: Promoting and Protecting the Health of the Public (IOM)**, 132:1644–ghn

**$\gamma$ -Glutamyl transpeptidase (GGT)**, in *Helicobacter pylori* infection, 132:1642–tmig, 132:1820

**Gap junctions**, in necrotizing enterocolitis, interferon- $\gamma$  and, 132:2395

**Gastric banding**, 132:2253

**Gastric bypass**, 132:2253

**Gastric cancer**

FHL2 suppression and, 132:1066

*Helicobacter pylori* and, 132:833–tmig, 132:1009, 132:1177–e, 132:2076–c

toll-like receptor 4 gene polymorphism and, 132:905

**Gastric distention**, in functional dyspepsia, hypersensitivity to, 132:1684

**Gastric metaplasia**, amphiregulin deficiency and (mice), 132:1804, 132:2053–e

**Gastric ulcers**, time trends in mortality, 132:2320

**Gastroenteritis**, acute, irritable bowel syndrome after, 132:458–ss, 132:481–ccig

**Gastroenterology**, pediatric, state of, 132:434–p

**Gastroenterology and Hepatology News**

Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus, 132:5

FDA Licenses First Biologic Product to Prevent Hepatitis B Reinfection in Liver Transplant Patients, 132:2281

FDA Risk Assessment Document Declares Food From Some Cloned Animals Safe, 132:835

The Food and Drug Administration Approves Humira, 132:1644

The Food and Drug Administration Reinforces Commitment to Drug Safety, 132:1644

Gail Hecht New American Gastroenterological Association Vice President-Elect, 132:1646

Gut Microbes May Affect Obesity, 132:836

HCV Findings Presented at EASL: Long-Term Follow-Up and the Criteria of a Cure, 132:2281–ghn

Interim Results Presented at EASL From Prove 1 Clinical Trial of Investigational Telaprevir in Patients with Genotype 1 Hepatitis C, 132:2282

Keith Lindor is New Editor-In-Chief of *Hepatology*, 132:6

Mark Donowitz Reflects on the Future of Clinical Gastroenterology, 132:1645

Nicholas LaRusso, Physician Scientist, Is

the New AGA Institute President, 132:2283

Pioglitazone Trial for NASH: Results Show Promise, 132:836

Study Identifies a Gene for Inflammatory Bowel Disease, 132:5

Study Points to Increased Colorectal Cancer Screening Among Veteran's Affairs Patients, 132:4

Whole-Body Scans for Colorectal Cancer Diagnosis, 132:473

**Gastroenterology Core Curriculum**, 132:2012–agai

**Gastroesophageal reflux disease (GERD)**

esophagitis associated with, cytokines and dysmotility in, 132:154

lifestyle and risk factors for, twin study of, 132:87

in neonates, development of peristalsis and, 132:1718

obesity and pathogenesis of, 132:883  
refractory, impedance/pH monitoring in, 132:1621–ss

**Gastroesophageal reflux symptoms**, in opera choristers, 132:890

**Gastrointestinal stromal tumors (GISTs)**, AGAI Technical Review statements on, 132:822–c

**Gastrotoxicity**, hydrogen-sulfide releasing NSAIDs and, 132:2–tmig, 132:261

**Gemcitabine**, for pancreatic cancer, 132:2607–ss

**Gender**

and colorectal cancer screening, 132:2605–ss

and gastroenterology career, 132:1598–agai

and liver cancer, 132:2557–rev

and obesity, 132:2087

**Gene silencing**, application to gastrointestinal diseases, 132:2291–ccig

**GERD**. *See* Gastroesophageal reflux disease

**Ghrelin**, and appetite, 132:2116

**Glial-derived s-nitrosoglutathione (GSNO)**, and barrier function, 132:1344, 132:1615–e

**Glucagon-like peptide 1 (GLP-1)**, in appetite and obesity, 132:2116, 132:2131

**Glucose-dependent insulinotropic polypeptide (GIP)**, 132:2131

**Glucose metabolism**

CNS fuel sensing in, 132:2158

liver, quantification by PET, 132:531, 132:794–e

in nonalcoholic fatty liver disease, 132:2191

**Glycogen synthase kinase 3 $\beta$**



- (**GSK3 $\beta$** ), in colorectal cancer, 132:208
- Goblet cell differentiation**, matrix metalloproteinase 9 and, 132:1877
- Gonadotropin-releasing hormone (GnRH)**, in buserelin-induced pseudo-obstruction, 132:45
- gp130**, in hepcidin activation, STAT3 and, 132:294, 132:447–e
- Granisetron**, for nausea and vomiting, 132:397–rev
- Granzyme A**, in hepatocellular carcinoma, regulatory T cells and, 132:2328
- Granzyme B**, in hepatocellular carcinoma, regulatory T cells and, 132:2328
- Growth differentiation factor-15 (GDF-15)**, in colorectal cancer, 132:1204–c
- Growth hormone**, for nonalcoholic steatohepatitis, 132:938
- grp78**, in endoplasmic stress response, IL-10 and, 132:190
- Gut hormones**, and appetite, 132:2116
- Hath1**, in colorectal cancer, targeting of, 132:208
- HCT-1026 (nitrofuribiprofen)**, and portal hypertension (rat), 132:709
- Heart disease**, obesity and, 132:2181
- Hecht, Gail**, 132:1646–ghn
- Helicobacter pylori**, 132:481–ccig  
Abl activation by, 132:1309  
and gastric cancer, 132:833–tmig, 132:1009, 132:1177–e, 132:2076–c  
host response to, 132:905  
invasive nature of, 132:833–tmig, 132:1009, 132:1177–e  
T-cell suppression in,  $\gamma$ -glutamyl transpeptidase and, 132:1642–tmig, 132:1820  
and time trends in ulcer mortality, 132:2320  
transcription factor activation in infection (gerbils), 132:1024
- Helminth infection**, and colitis (mice), 132:1320
- Hemangioma**, capillary, of small intestine, 132:1656–clin, 132:2084–clin
- Hemochromatosis**  
ceruloplasmin as modifier of (mice), 132:679  
penetrance of (mice), 132:805–e
- Hemophiliacs**, hepatitis C virus clearance in, 132:1634–c
- HepaGam B**, FDA approval of, 132:2281–ghn
- Hepatectomy**, partial, liver regeneration induced by, bone marrow cell differentiation in, 132:1077
- Hepatic glucose uptake (HGU)**, quantification by PET, 132:531, 132:794–e
- Hepatic oval cells**, bone-marrow derived, differentiation of, 132:1077
- Hepatic stellate cells**  
activation of, gene expression during, 132:1937, 132:2059–e  
Forkhead transcription factor FoxO1 and, 132:1434
- Hepatic venous pressure gradient**, measurement of, 132:1201–c
- Hepatitis**  
alcoholic  
eNOS in, gene and protein expression of, 132:2533  
gene expression and severity of, 132:687  
T-cell-mediated, IL-28A in, 132:358
- Hepatitis B e antigen (HBeAg)**, seroconversion in children, 132:2340
- Hepatitis B immunoglobulin (HBIG)**, low-dose, with lamivudine, post-transplant use of, 132:931
- Hepatitis B surface antigen (HBsAg)**, clearance in lamivudine treatment, 132:543, 132:2617–c
- Hepatitis B vaccine**, universal, in Taiwan, impact and implications of, 132:1287
- Hepatitis B virus (HBV)**  
chronic  
in children, viremia and HBeAg seroconversion in, 132:2340  
drug resistance in, 132:1574–rev  
IL-10 and clearance of, 132:2611–ss  
lamivudine for, 132:1586–rev  
HBsAg clearance with, 132:543, 132:2617–c  
post-transplant recurrent, prevention of HepaGam B for, 132:2281–ghn  
lamivudine and low-dose HBIG for, 132:931  
steatosis in, 132:1955  
treatment of, negotiating maze of, 132:1586–rev
- Hepatitis B X-protein (HBx)**  
in hepatocellular carcinoma  
aberrant epigenetic modifications induced by, 132:1476  
PIN1 and, 132:1088, 132:1180–e, 132:2618–c  
hepatosteatosis induced by, 132:1955
- Hepatitis C virus (HCV)**  
acute  
CD4 and CD8 T-cell responses in, 132:654  
neutralizing antibody in, 132:654  
adaptive immunity in, 132:654, 132:667, 132:801–e  
alcohol use in, effect on dendritic cell function and NS5 clearance (mice), 132:471–tmig, 132:698  
B-cell lymphomas with, 132:1205–c  
chronic  
B cell responses in, 132:801–e  
interferon-induced depression in, serotonin-1A receptor gene as predictor of, 132:1279  
interferon response in, SOCS-3 and, 132:733  
neutralizing antibody in, 132:667  
Silymarin for, 132:1925  
T-cell responses in, 132:667, 132:801–e  
clearance in hemophiliacs and beta-thalassemics, 132:1634–c  
EASL report on long-term follow-up and criteria of cure, 132:2281–ghn  
genotype 1 nonresponders in, SCH 503034 and pegylated interferon  $\alpha$ -2b for, 132:1270, 132:1611–e  
IL-10 and clearance of, 132:2611–ss  
innate immunity in, 132:801–e  
life cycle of, as therapeutic target, 132:1979–rev  
liver transplantation for, access to, 132:1152  
mutagenic effect of ribavirin in, 132:921, 132:1757, 132:2050–e  
post-transplant recurrent, peginterferon  $\alpha$ -2b and ribavirin for, 132:1746  
retreatment of, dose reduction of ribavirin and peginterferon in, 132:103  
small molecule regulators of, screen for, 132:311  
steatosis in, 132:1955  
survivor's guide to living with, 132:2614–pmr  
telaprevir and peginterferon for, 132:5ghn, 132:1767, 132:2282–ghn  
telaprevir resistance in, 132:1767  
treatment options for, 132:1611–e  
vaccine-induced T-cell responses in, 132:1626–ss
- Hepatitis delta virus (HDV)**, transforming growth factor- $\beta$  in, antigen modulation of, 132:343
- Hepatocellular carcinoma (HCC)**  
coffee and risk of, 132:1740  
epidemiology of, 132:2557–rev

- hepatitis B X-protein in  
 aberrant epigenetic alterations induced  
 by, 132:1476  
 interaction with PIN 1, 132:1088,  
 132:1180–e, 132:2618–c  
 liver transplantation for, access to, 132:  
 1152  
 molecular carcinogenesis of, 132:2557–  
 rev  
 noncoding RNA in, 132:330  
 p53-mutant, telomerase deletion in, 132:  
 1465  
 regulatory T cell increase in, 132:2328  
 sodium iodide symporter in, 132:1495  
 tumorigenic stem/progenitor cells in,  
 132:2542
- Hepatocytes**  
 bone marrow cell differentiation to, 132:  
 1077  
 in liver injury, IKK $\gamma$ /NEMO and, 132:  
 2504, 132:2601–e  
 TNF-induced apoptosis of, RelA/p65 and  
 (mice), 132:2489, 132:2601–e  
 xenotransplantation of (porcine to pri-  
 mate), 132:321, 132:450–e
- Hepatology**, new editor-in-chief of,  
 132:6–ghn
- Hepatology**, pediatric, state of, 132:  
 434–p
- Hepatosteatosis (fatty liver)**  
 adipose differentiation-related protein  
 and, 132:1947  
 alcoholic, complement and, 132:1117  
 hepatitis B X-protein and, 132:1955  
 nonalcoholic  
 adipose differentiation-related protein  
 in, 132:1947  
*versus* alcoholic liver disease, index for,  
 132:2076–c  
 epidemiology of, 132:2191  
 FoxO1 and stellate cell activation in,  
 132:1434  
 obesity and  
 inflammation in, 132:2169  
 lipid and glucose metabolism in,  
 132:2191
- Hepatotoxicity**  
 of acetaminophen, mild hypothermia for,  
 132:3–tmig, 132:372  
 of diclofenac, genetic susceptibility to,  
 132:272
- Hepcidin**  
 activation of, STAT3 and, 132:294, 132:  
 447–e  
 regulation of, transferrin receptor 2 in,  
 132:301
- HFE protein**, in hemochromatosis, 132:  
 679, 132:805–e
- High-density-lipoprotein (HDL)  
 cholesterol**, low, in obesity,  
 132:2181
- High-frequency microsatellite in-  
 stability sporadic colorec-  
 tal cancer**  
 activin signaling in, 132:633  
 CpG island methylator phenotype  
 (CIMP) in, 132:127
- High-grade dysplasia, in Barrett's  
 esophagus**  
 endoscopic trimodal imaging of, 132:  
 2586–agai  
 long-term outcome of treatment, 132:  
 1211–tmig, 132:1226,  
 132:1607–e
- High-resolution endoscopy  
 (HRE)**, of Barrett's esophagus,  
 132:2586–agai
- High-throughput screen**  
 for small molecule regulators of hepatitis  
 C virus, 132:311  
 for somatic genetic alterations in colorec-  
 tal cancer, 132:645
- Hip fracture**, proton pump inhibitors  
 and, 132:2063–ss
- HLA-DQ2 homozygotes**, in celiac  
 disease, 132:2585–agai
- Hormones**  
 gut, and appetite, 132:2116  
 sex steroid, and macrophage migration  
 inhibitory factor, in colitis (rat),  
 132:982
- H-ras**, RhoA/ROCK inhibition by, 132:  
 1401
- hTERT**, FHL2 suppression and, 132:1066
- HU210**, in acute pancreatitis, cannabi-  
 noids and, 132:1968
- HULC**, in liver cancer, 132:330
- Human Genome Epidemiology  
 Network (HuGE Net)**, 132:  
 839–ccig
- Humira**. *See* Adalimumab
- HuR**, inhibition by CUGBP2, in COX-2  
 mRNA translation, 132:1055
- Hydrogen sulfide-releasing  
 NSAIDs**, 132:2–tmig, 132:261
- Hymenolepis diminuta**, and colitis  
 (mice), 132:1320
- Hyperglycemia**, in obesity, and cancers  
 of colon, prostate, and pancreas,  
 132:2208
- Hyperinsulinemia**, in colorectal can-  
 cer, 132:2208
- Hypersensitivity**  
 to gastric distention, in functional dys-  
 pepsia, 132:1684  
 in irritable bowel syndrome  
 normalization of, 132:464–c  
 postinfective, brain-gut axis alterations  
 and, 132:1375  
 vanilloid 1 receptor in, 132:470–tmig,  
 132:615
- Hypothalamus**, fuel sensing in, and  
 energy balance, 132:2158
- Hypothermia**, mild, for acetaminophen  
 toxicity, 132:3–tmig, 132:372
- IBD**. *See* Inflammatory bowel disease
- IBD5**, in Crohn's disease, 132:1665, 132:  
 2045–e
- IBS**. *See* Irritable bowel syndrome
- IKK $\gamma$ /NEMO**, expression in liver injury,  
 132:2504, 132:2601–e
- Ileal Crohn's disease**, *ATG16L1* and,  
 132:1665, 132:2045–e
- Imaging and Advanced Technol-  
 ogy**  
 Imaging the Pancreas: Into the Deep,  
 132:484  
 Improving Colorectal Adenoma Detec-  
 tion: Technology or Technique?,  
 132:1221  
 Intraluminal Endoscopic Surgery: The  
*Scioto* Returns, 132:848  
 Molecular Imaging in Gastrointestinal  
 Disease, 132:11  
 The Power of Silence: Application of  
 Small Interfering RNAs to Gas-  
 trointestinal Diseases, 132:2291  
 Update on Small Bowel Imaging, 132:  
 1651
- Immune dysregulation, polyendo-  
 crinopathy, enteropathy,  
 X-linked (IPEX) syn-  
 drome**  
*FOXP3* gene and, 132:1694, 132:1705  
 severe food allergy variant of, 132:1705
- Immune response**. *See also* specific  
 responses and diseases  
 in celiac disease, 132:1245  
 in Crohn's disease, 132:2609–ss  
 in hepatitis C, 132:654, 132:667, 132:  
 801–e  
 in hepatocellular carcinoma, 132:2328  
 in irritable bowel syndrome, 132:913
- Impedance/pH monitoring**, in re-  
 fractory GERD, 132:1621–ss
- Incomplete colonoscopy**, 132:2277–  
 tmig, 132:2297, 132:2588–e
- Incretins**, biology of, 132:2131
- Inducible nitric oxide synthase  
 (iNOS)**, bone-marrow derived,  
 in colitis, 132:1778
- Infants**  
 esophageal peristalsis in, development of,  
 132:1718  
 parenteral nutrition-associated cholestasis  
 in, oral erythromycin and de-  
 crease in, 132:1726  
 serotonin release from enterochromaffin  
 cells in (guinea pig), 132:2438

**Infectious gastroenteritis (IGE),**  
irritable bowel syndrome after,  
132:458–ss

**Inflammatory bowel disease.** *See*  
*also* Crohn's disease; Ulcerative  
colitis

*ATG16L1* and, 132:1665, 132:2045–e  
bacteria/microbes and, 132:481–ccig  
bone marrow-derived inducible nitric  
oxide synthase in, 132:1778  
challenges in, 132:2075–pmr  
clinical dilemmas in, 132:820–pmr  
fractalkine in, 132:139  
genome-wide association studies of, 132:  
2045–e  
IL-10 and endoplasmic stress response in,  
132:190  
IL-21 enhancement of MIP-3 $\alpha$  in, 132:  
166  
IL-23 receptor gene in, 132:5ghn, 132:  
481–ccig, 132:1641–tmig, 132:  
1657, 132:2045–e  
matrix metalloproteinase 9 in, 132:1877  
myosin light chain kinase and barrier  
dysfunction in, 132:454–ss  
R-spondin1 in (mice), 132:1331  
stem cell therapy in (mice), 132:944,  
132:1171–e  
T-cell LIGHT and barrier disruption in,  
132:2279–tmig, 132:2383  
*TUCAN/CARD8* in, lack of association  
found, 132:2078–c, 132:2080–c

**Infliximab,** for Crohn's disease  
oral lichenoid reaction to, 132:488–clin,  
132:829–clin  
in pediatric patients, 132:831–tmig,  
132:863, 132:1167–e

**Institute of Medicine (IOM),** 132:  
1644–ghn

### **Insulin resistance**

adipose differentiation-related protein  
and, 132:1947  
in colorectal cancer, 132:2208  
in nonalcoholic fatty liver disease, 132:  
2191  
and nonalcoholic steatohepatitis (rat),  
132:282, 132:444–e  
obesity-induced inflammation and, 132:  
2169  
 $\alpha$ 4-Integrin, monoclonal antibodies to,  
for Crohn's disease, 132:1641–  
tmig, 132:1672

### **Interferon**

depression induced by, serotonin-1A re-  
ceptor gene as predictor of, 132:  
1279  
pegylated. *See* Peginterferon

**Interferon- $\alpha$ ,** for chronic hepatitis C,  
SOCS-3 and response to, 132:733

**Interferon  $\alpha$ -2b,** for hepatitis B, 132:  
1586–rev

**Interferon- $\gamma$ ,** in necrotizing enterocoli-  
tis, enterocyte migration inhibi-  
tion by, 132:2395

**Interferon-stimulated responsive  
element (ISRE),** 132:1024

**Interleukin-5,** monoclonal antibody to,  
for eosinophilic esophagitis, 132:  
2586–agai

**Interleukin-6**  
in cholangiocarcinoma, SOCS-3 silencing  
and, 132:384  
in GERD-associated esophageal dysmo-  
tility, 132:154  
in hepcidin activation, STAT3 and, 132:  
294, 132:447–e

**Interleukin-10**  
and endoplasmic stress response, 132:190  
and viral clearance, 132:2611–ss

**Interleukin-15,** inhibition of TGF- $\beta$  in  
celiac disease by, 132:994, 132:  
1174–e

**Interleukin-17,** in colitis, IL-23 mono-  
clonal antibodies and (mice), 132:  
2278–tmig, 132:2359

**Interleukin-21,** in inflammatory bowel  
disease, MIP-3 $\alpha$  enhancement by,  
132:166

**Interleukin-23,** monoclonal antibodies  
to, reversal of active colitis by,  
132:2278–tmig, 132:2359

**Interleukin-28A,** in T-cell-mediated  
liver injury, 132:358

**Interleukin-1 $\beta$ ,** in GERD-associated  
esophageal dysmotility, 132:154

**Interleukin-23 receptor (IL23R)**  
gene, in inflammatory bowel  
disease, 132:5ghn, 132:481–ccig,  
132:1641–tmig, 132:1657, 132:  
2045–e

**Internal anal sphincter (IAS),** basal  
tone in, H-*ras* inhibition of  
RhoA/ROCK and, 132:1401

**Interstitial cells of Cajal,** pacemaker  
activity in small intestine, 132:  
1852, 132:2057–e

### **Intestinal epithelial cells**

in celiac disease, tissue transglutaminase  
and, 132:1245  
in Crohn's disease, MICA-NKG2D inter-  
actions and, 132:2346  
differentiation of, matrix metalloprotein-  
ase 9 and, 132:1877  
in *Elf-3* deficiency, TGF- $\beta$ RII rescue of  
(mice), 132:1410  
growth and survival of, probiotic soluble  
proteins and, 132:562

IL-10 and endoplasmic stress response in,  
132:190

IL-21 and MIP-3 $\alpha$  synthesis by, 132:166  
releasing antigen-presenting vesicles,  
132:1866

Wnt/TCF signature in, 132:628

**Intestinal epithelial exosomes,**  
function of, 132:1866

**Intestinal resection,** *Math1* and cellu-  
lar response to, 132:2478

**Intrahepatic cholestasis,** inherited,  
resequencing chip for diagnosis  
of, 132:119

**Intraluminal endoscopic surgery,**  
132:848–ccig

**Intrinsic occult reflex,** and large  
bowel transit, 132:1912

**IPEX syndrome.** *See* Immune dysregu-  
lation, polyendocrinopathy, enter-  
opathy, X-linked syndrome

### **Iron homeostasis**

ceruloplasmin and (mice), 132:679  
hepcidin activation in, 132:294, 132:  
447–e  
transferrin receptor 2 and (mice), 132:  
301

### **Irritable bowel syndrome**

bowel urgency in, 132:38  
with constipation  
lubiprostone for, 132:2586–agai  
tegaserod for, 132:397–rev  
withdrawal from market, 132:2287–p  
immune activation in, 132:913  
mast cell-dependent excitation in,  
132:26  
physician answers to questions about,  
132:2615–pmr  
p11 mRNA expression in, 132:1–tmig,  
132:17  
postinfectious, 132:458–ss, 132:481–  
ccig, 132:1375  
probiotics for, 132:813–ss  
serotonin reuptake transporter (SERT) in,  
132:1–tmig, 132:17, 132:437–e  
visceral hypersensitivity in  
normalization of, 132:464–c  
postinfective, brain-gut axis alterations  
and, 132:1375  
vanilloid 1 receptor in,  
132:470–tmig, 132:615

**Islet regeneration,** pancreatic ductal  
progenitor cells for, 132:720

**JAG1,** in intrahepatic cholestasis, testing  
for, 132:119

**Journal Policy,** Conflicts of Interest and  
Disclosures in Publications, 132:  
841

**Julius M. Friedenwald Medal,** pre-  
sented to Freston, 132:2580–agai

- Kelly, Howard Atwood**, 132:10–bio
- Keratins**, cross-linked, transglutaminase 2 and, 132:1515
- Lactobacillus rhamnosus GG* (LGG)**, effect on cell growth and survival, 132:562
- Lamivudine**  
for hepatitis B prevention, post-transplant, with low-dose HBIG, 132:931  
for hepatitis B treatment, 132:1586–rev  
HBsAg clearance in, 132:543, 132:2617–c
- Laparoscopic adjustable gastric banding**, 132:2253
- Large bowel transit**, enteric occult reflex and, 132:1912
- Large hepatitis delta antigen (LHDag)**, and transforming growth factor- $\beta$ , 132:343
- LaRusso, Nicholas F.**, 132:2005–agai, 132:2283–ghn
- Lectin-based inhibitors**, of CFTR and secretions in cholera, 132:1234
- Leptin**, in appetite and obesity, 132:2103
- Leukocytes**, in colitis, CD40-CD40 ligand and, 132:955
- Lialda (MMX mesalamine)**, for active ulcerative colitis, 132:1–tmig, 132:66
- Lichenoid reaction**, oral, in Crohn's disease, 132:488–clin, 132:829–clin
- Lifestyle modification**, for obesity, 132:2226
- LIGHT**, disruption of epithelial barrier by, 132:2279–tmig, 132:2383
- Lindor, Keith**, 132:6–ghn
- Lipid metabolism**  
hepatic  
adipose differentiation-related protein and, 132:1947  
hepatitis B X-protein and, 132:1955  
in nonalcoholic fatty liver disease, 132:2191  
obesity and, 132:2181, 132:2191
- Liver and Pancreatic Diseases Management**, 132:1196–pmr
- Liver cancer**  
coffee and risk of, 132:1740  
epidemiology of, 132:2557–rev  
hepatitis B X-protein in  
aberrant epigenetic alterations induced by, 132:1476  
interaction with PIN 1, 132:1088, 132:1180–e, 132:2618–c  
molecular carcinogenesis of, 132:2557–rev  
noncoding RNA in, 132:330  
p53-mutant, telomerase deletion in, 132:1465  
regulatory T cell increase in, 132:2328  
sodium iodide symporter in, 132:1495  
transplantation for, access to, 132:1152  
tumorigenic stem/progenitor cells in, 132:2542
- Liver enlargement**, injury-associated, transglutaminase 2 and, 132:1515
- Liver failure**, xenotransplantation of hepatocytes for (porcine to primate), 132:321, 132:450–e
- Liver fibrogenesis**  
Forkhead transcription factor FoxO1 in, 132:1434  
hepatic stellate cell activation in, 132:1937, 132:2059–e  
mediators, in alcoholic hepatitis, 132:687
- Liver glucose metabolism**, quantification by PET, 132:531, 132:794–e
- Liver injury**  
acetaminophen-induced, mild hypothermia for, 132:3–tmig, 132:372  
diclofenac-induced, genetic susceptibility to, 132:272  
drug-induced, chronic liver disease from, 132:2067–ss  
IKK $\gamma$ /NEMO expression and degree of, 132:2504, 132:2601–e  
T-cell-mediated, IL-28A in, 132:358
- Liver regeneration**, 2-AAF/PHx induced, bone marrow cell differentiation in, 132:1077
- Liver-specific transferrin receptor 2**, 132:301
- Liver transplantation**  
access to, management of, 132:1152–srr  
hepatitis B recurrence prevention after HepaGam for, 132:2281–ghn  
lamivudine and low-dose HBIG for, 132:931  
hepatitis C recurrence prevention after, peginterferon  $\alpha$ -2b and ribavirin for, 132:1746
- Living with Hepatitis C: A Survivor's Guide**, 132:2614–pmr
- Low HDL cholesterol**, in obesity, 132:2181
- L-type calcium channels**, vasoactive intestinal peptide and, 132:1212–tmig, 132:1388
- Lubiprostone**, for irritable bowel syndrome, 132:2586–agai
- Luschka, Hubert von**, 132:1216–bio
- Lymphoma**  
B-cell, with hepatitis C infection, 132:1205–c  
enteropathy-type T-cell, whole-genome analysis and HLA genotyping of, 132:1902
- Lymphopenia**, in autoimmune enteropathy, 132:1694
- Lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells (LIGHT)**, disruption of epithelial barrier by, 132:2279–tmig, 132:2383
- Lysophosphatidic acid type 2 receptor**, in radioprotection, 132:1834
- Macrophage migration inhibitory factor (MIF)**, in colitis, sex steroids and (rat), 132:982
- Magnetic resonance imaging (MRI)**, 132:11–ccig  
of pancreas, 132:484–ccig
- Major histocompatibility complex class II/peptide complexes**, intestinal epithelial exosomes bearing, 132:1866
- Making Sense of IBS: A Physician Answers Your Questions About Irritable Bowel Syndrome**, 132:2615–pmr
- MAL**, in colorectal cancer, DNA hypermethylation of, 132:1631–c
- MalH-lectin**, in cholera, CFTR and secretion inhibition by, 132:1234
- Malignant digestive endocrine tumors (MDETs)**, survival from, 132:899
- Mallory body (MB) inclusions**, transglutaminase 2 and, 132:1515
- Mammalian target of rapamycin (mTOR)**, fuel sensing by, 132:2158
- Mast cells**, in irritable bowel syndrome, 132:26
- Math1**, intestine-specific ablation of, 132:2478
- Matrix metalloproteinase 9 (MMP-9)**, and goblet cell differentiation, 132:1877
- Medicare payments**, law freezing, 132:474–ghn
- Mepolizumab**, for eosinophilic esophagitis, 132:2586–agai
- Mesalamine, MMX**, for active ulcerative colitis, 132:1–tmig, 132:66
- Meta-analysis**, of gene association studies, 132:839–ccig
- Methionine intake**, and pancreatic cancer risk, 132:113, 132:441–e



**Methylation**

connection with cancer, 132:2069–ss  
of *MAL*,  
in colorectal cancer, 132:1631–c  
in ulcerative colitis-associated neoplasias,  
132:1254

**Mezavant (MMX mesalamine)**, for  
active ulcerative colitis, 132:1–  
tmig, 132:66

**MICA interactions**, of  
CD4<sup>+</sup>NKG2D<sup>+</sup> T cells, in  
Crohn's disease, 132:2346

**Microbes**

gut, and obesity, 132:836–ghn  
role in intestinal disorders, 132:481–  
ccig, 132:551, 132:576, 132:  
797–e, 132:2313, 132:2594–e

**Microcirculation**, in inflammatory  
bowel disease, stem cell therapy  
and (mice), 132:944, 132:1171–e

**Microsatellite instability sporadic colorectal cancer**

activin signaling in, 132:633  
CpG island methylator phenotype  
(CIMP) in, 132:127

**Microvillous inclusion disease**,  
132:1225–clin, 132:1639–clin

**Milk thistle**, for chronic hepatitis C,  
132:1925

**MIP-3 $\alpha$** , in inflammatory bowel disease,  
IL-21 enhancement of, 132:166

**Mitochondrial death pathway**, for  
pancreatic stellate cells, tocotrien-  
ols and (rat), 132:2518

**Mitosis**, abnormal, *APC* inactivation and,  
132:2448

**MK-001 (Silymarin extract)**, for  
chronic hepatitis C, 132:1925

**MMX mesalamine**, for active ulcerative  
colitis, 132:1–tmig, 132:66

**Model for End-stage Liver Disease  
(MELD)**, 132:1261

**Molecular imaging**, in gastrointestinal  
disease, 132:11–ccig

**Monkeys**, porcine hepatocyte transplant  
to, 132:321, 132:450–e

**Motility**

anorectal, *H-ras* inhibition of RhoA/  
ROCK and, 132:1401  
colonic, vasoactive intestinal peptide and,  
132:1212–tmig, 132:1388  
esophageal  
in achalasia, treatment of, 132:811–ss  
angiotensin II and, 132:249  
cytokines and, 132:154

**Mouse atonal homolog 1  
(Math1)**, intestine-specific ab-  
lation of, 132:2478

**MUC-2 expression**, matrix metallopro-  
teinase 9 and, 132:1877

**Multi Matrix System (MMX) me-**

**salamine**, for active ulcerative  
colitis, 132:1–tmig, 132:66

**Munc18c**, in alcoholic pancreatitis, 132:  
1527

***Mycobacterium avium subspe-*  
*cies paratuberculosis***, in  
Crohn's disease, 132:2313, 132:  
2594–e

**Myeloperoxidase**, in colonic stress  
response, 132:1791

**Myenteric interstitial cells of Ca-  
jal**, pacemaker activity in small  
intestine, 132:1852, 132:2057–e

**Myosin light chain kinase**  
in inflammatory bowel disease,  
132:454–ss  
T-cell light and, 132:2279–tmig, 132:  
2383

**Myotomy**, for achalasia, for pneumatic  
dilation, 132:811–ss

**NALD**. See Nonalcoholic fatty liver disease

**Narrow band imaging (NBI)**, of  
Barrett's esophagus, 132:1189–  
ss, 132:2586–agai

**NASH**. See Nonalcoholic steatohepatitis  
**Natalizumab**, for active Crohn's disease,  
132:1641–tmig, 132:1672

**National Institute of Diabetes and  
Digestive and Kidney Dis-  
ease (NIDDK)**, 132:1219

**National Institutes of Health  
(NIH)**

attrition of young physician-scientists  
from, 132:477–p  
research climate for, 132:1647–ccig

**National Institutes of Health  
(NIH) Reform Act of  
2006**, 132:474–ghn

**Nausea**, serotonin antagonists for, 132:  
397–rev

**Neck abscess**, perforated diverticulum  
with, 132:1655–clin, 132:2083–  
clin

**Necrotizing enterocolitis (NEC)**,  
interferon- $\gamma$  inhibition of entero-  
cyte migration in, 132:2395

**NEMO**, expression in liver injury, 132:  
2504, 132:2601–e

**Neonates**

esophageal peristalsis in, development of,  
132:1718

parenteral nutrition-associated cholestasis  
in, oral erythromycin and de-  
crease in, 132:1726

serotonin release from enterochromaffin  
cells in (guinea pig), 132:2438

**Netter's Gastroenterology**, 132:  
1196–pmr

**Neuroendocrine regulation**, of  
cholangiocytes, 132:415–srr

**Neuropathic pain**, in chronic pancre-  
atitis, 132:1546, 132:1618–e

**Neuroscience**, enteric, 132:1217–ccig

**Neutralizing antibody (nAb)**

in acute hepatitis C, 132:654  
in chronic hepatitis C, 132:667

**Nicotinamide adenine dinucle-  
otide phosphate (NADPH)  
oxidase**, in alcoholic hepatitis,  
132:687

***Nippostrongylus brasiliensis*** in-  
fection, visceral hypersensitivity  
after (mice), 132:1375

**Nitric oxide**, and large bowel transit,  
132:1912

**Nitric oxide-releasing cyclooxy-  
genase inhibitor**, and  
portal hypertension (rat), 132:  
709

**Nitric oxide synthase**

endothelial, in alcoholic hepatitis, 132:  
2533

inducible, bone-marrow derived, in coli-  
tis, 132:1778

**Nitric oxide synthase 2**, in colonic  
stress response, 132:1791

**Nitroflurbiprofen**, and portal hyper-  
tension (rat), 132:709

**S-Nitrosoglutathione**, glial release of,  
and barrier function, 132:1344,  
132:1615–e

**NKG2D-activating receptor**, in  
Crohn's disease, 132:2346

***NOD2 (CARD15) gene***, in Crohn's  
disease, 132:481–ccig, 132:576,  
132:1665, 132:2045–e

**Nonalcoholic fatty liver disease (NALD)**

adipose differentiation-related protein in,  
132:1947

*versus* alcoholic liver disease, index for,  
132:2076–c

epidemiology of, 132:2191

FoxO1 and stellate cell activation in,  
132:1434

obesity and

inflammation in, 132:2169

lipid and glucose metabolism in, 132:  
2191

**Nonalcoholic steatohepatitis (NASH)**

growth hormone for, 132:938

insulin resistance and (rat), 132:282,  
132:444–e

pioglitazone for, 132:836–ghn

**Noncoding RNA**, in liver cancer, 132:  
330

### Nonsteroidal anti-inflammatory drug(s) (NSAIDs)

gastrointestinal complications of, 132:469–tmig, 132:498  
hydrogen-sulfide releasing, 132:2–tmig, 132:261

### Nonsteroidal anti-inflammatory drug-activated gene (NAG-1), in colorectal cancer, 132:1204–c

**NOSIP**, in alcoholic hepatitis, 132:2533

**NOSTRIN**, in alcoholic hepatitis, 132:2533

**NS5**, in hepatitis C  
alcohol and clearance of (mice), 132:471–tmig, 132:698  
ribavirin and mutation of, 132:1757, 132:2050–e

### Nuclear factor-κB

friend or foe in liver, 132:2601–e  
in *Helicobacter pylori* infection (gerbils), 132:1024  
in hepatitis C, Silymarin and, 132:1925  
in liver injury, IKKγ/NEMO modulation of, 132:2504, 132:2601–e  
in TNF-induced hepatocyte apoptosis (mice), 132:2489, 132:2601–e

**Nucleos(t)ide analogues**, for hepatitis B, 132:1586–rev

### Nutrition

parenteral, cholestasis in preterm neonates with, oral erythromycin and decrease in, 132:1726  
pediatric, state of, 132:434–p

### Obesity

adipose-derived factors in, 132:2103  
adipose differentiation-related protein in, 132:1947  
AGAI task force report on, 132:2272  
and atherogenic dyslipidemia, 132:2181  
bacteria/microbes and, 132:481–ccig  
and colorectal cancer, 132:816–ss, 132:2208  
definitions of, 132:2087  
drug treatment for, 132:2239  
epidemiology of, 132:2087  
and GERD risk, 132:87  
gut hormones and, 132:2116  
gut microbes and, 132:836–ghn  
incretins in, 132:2131  
inflammation induced by, pathogenic role of, 132:2169  
lifestyle modification for, 132:2226  
management of, 132:2075–pmr  
and pancreatic cancer, 132:2208  
and prostate cancer, 132:2208  
silence *versus* noise about, 132:2085  
surgery for, 132:462–pmr, 132:2253  
and transient lower esophageal sphincter relaxation, 132:883

**Obscure gastrointestinal bleeding**, push *versus* capsule enteroscopy in, 132:831–tmig, 132:855

**Octadecenyl thiophosphate (OTP)**, in radioprotection, 132:1834

**Octreotide**, for polycystic liver disease, 132:1104

**Odorant stimulation**, of enterochromaffin cells, and serotonin release, 132:1643–tmig, 132:1890

**Olfactory receptors**, intestinal, 132:1643–tmig, 132:1890

**Ondansetron**, for nausea and vomiting, 132:397–rev

**OPC-6535 (tetomilast)**, for active ulcerative colitis, 132:76

**Opera choristers**, reflux symptoms in, 132:890

**Opioids**, endogenous, control of pancreatic cancer pain by, 132:1191–ss

**Optical imaging**, 132:11–ccig

**Oral lichenoid reaction**, in Crohn's disease, 132:488–clin, 132:829–clin

**Orlistat**, for obesity, 132:2239

**Ormond, John Kelso**, 132:838–bio

**Overweight**, definition of, 132:2087

### Oxidative stress

in alcoholic hepatitis, 132:687  
in cancers of colon, prostate, and pancreas, 132:2208

**Oxyntic atrophy**, gastric metaplasia induced by, amphiregulin deficiency and, 132:1804, 132:2053–e

**Oxyntomodulin**, and appetite, 132:2116

**Pacemaker activity**, of interstitial cells of Cajal, in small intestine, 132:1852, 132:2057–e

### Pain

in acute pancreatitis, cannabinoids and, 132:1968

in chronic pancreatitis, cortical reorganization and, 132:1546, 132:1618–e

in pancreatic cancer, endogenous control of, and detection, 132:1191–ss

### Pancreas

development and disease of, 132:745–rev  
solid pseudopapillary tumor of, 132:1224–clin, 132:1638–clin

### Pancreatic cancer

biological therapies for, 132:2607–ss  
endogenous control of pain in, and detection, 132:1191–ss  
methionine intake and, 132:113, 132:441–e

microenvironment of, periostin-sustained fibrogenic stellate cells and, 132:1213–tmig, 132:1447

obesity and related metabolic disturbances and, 132:2208

vitamin B<sub>6</sub> intake and, 132:113

**Pancreatic cyst**, Von Hippel-Lindau disease type I with, 132:16–clin, 132:468–clin

**Pancreatic function testing**, 132:484–ccig

**Pancreatic head**, benign schwannoma of, 132:489–clin, 132:830–clin

**Pancreatic polypeptide**, and appetite, 132:2116

**Pancreatic progenitor cells**, in ductal epithelium, isolation of, 132:720

### Pancreatic stellate cells

apoptosis and autophagy of, tocotrienol-induced (rat), 132:2518

in microenvironment for cancer, periostin and, 132:1213–tmig, 132:1447

### Pancreatitis

acute, 132:1127–rev

AGAI medical position statement on, 132:2019–agai

AGAI technical review of, 132:2022–agai

pain in, cannabinoids and, 132:1968  
alcoholic, ectopic exocytosis in, 132:1527  
chronic, 132:1557–rev

imaging of, 132:484–ccig

pain in, cortical reorganization and, 132:1546, 132:1618–e

tocotrienol-induced stellate cell death in (rat), 132:2518

**Parasitic infection**, and colitis (mice), 132:1320

### Parenteral nutrition-associated

**cholestasis (PNAC)**, in preterm neonates, oral erythromycin and decrease in, 132:1726

**Partial hepatectomy**, liver regeneration induced by, bone marrow cell differentiation in, 132:1077

### Pediatrics

gastroenterology, hepatology, and nutrition, state of, 132:434–p

infliximab for Crohn's disease, 132:831–tmig, 132:863, 132:1167–e

viremia and HBeAg seroconversion in hepatitis B, 132:2340

### Peginterferon

for hepatitis B

PEG-IFN-α-2a, 132:1586–rev

PEG-IFN-α-2b, 132:1586–rev

with SCH 503034, for nonresponders, 132:1270, 132:1611–e

- for hepatitis C  
with ribavirin  
EASL report on, 132:2281–ghn  
for prevention of post-transplant recurrence, 132:1746  
for retreatment, 132:103  
with telaprevir, 132:5ghn, 132:1767, 132:2282–ghn
- Peptic ulcers**  
COXIBS and, 132:469, 132:490  
NSAIDs and, 132:469  
rofecoxib and, 132:490  
time trends in mortality, 132:2320
- Peptide YY**, and appetite, 132:2116
- Perforated diverticulum**, with neck abscess, 132:1655–clin, 132:2083–clin
- Perforative peritonitis**, on sclerosing encapsulating peritonitis, in alcoholic cirrhosis, 132:854–ccig, 132:1210–ccig
- Perforin**, in hepatocellular carcinoma, regulatory T cells and, 132:2328
- Periostin**, and microenvironment for pancreatic cancer, 132:1213–tmig, 132:1447
- Peristalsis**, esophageal, development in neonates, 132:1718
- Peritonitis**, perforative on sclerosing encapsulating, in alcoholic cirrhosis, 132:854–ccig, 132:1210–ccig
- Permeability**  
in colonic stress response, 132:1791  
glial-derived  $\alpha$ -nitrosoglutathione and, 132:1344, 132:1615–e  
matrix metalloproteinase 9 and, 132:1877  
myosin light chain kinase and, 132:454–ss  
toll-like receptor 2 regulation of, 132:1359
- Peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ )**  
in colonic stress response, 132:1791  
in hepatic steatosis, hepatitis B X-protein and, 132:1955  
in ulcerative colitis, 132:2585–agai
- Perspective**  
The Attrition of Young Physician-Scientists: Problems and Potential Solutions, 132:477  
Desperately Seeking Serotonin . . . A Commentary on the Withdrawal of Tegaserod and the State of Drug Development for Functional and Motility Disorders, 132:2287  
Opportunities and Challenges at NIDDK in Digestive Diseases Research, 132:1219  
State of Pediatric Gastroenterology, Hepatology, and Nutrition: 2006 and Beyond, 132:434
- Philosophical Transactions of the Royal Society [Biological Sciences] Theme Issue “Appetite,”** 132:819–pmr
- Phosphatidylinositol 3-kinase (PI3-K)**, in colonic epithelial cell survival, 132:587
- Phosphodiesterase-4 inhibitor**, for active ulcerative colitis, 132:76
- Photodynamic therapy (PDT)**, for high-grade dysplasia in Barrett’s esophagus, long-term outcome of, 132:1211–tmig, 132:1226, 132:1607–e
- Physical activity**  
and colorectal cancer survival, 132:456–ss  
and GERD risk, 132:87  
for obesity management, 132:2226
- Physical inactivity**, in obesity, and cancers of colon, prostate, and pancreas, 132:2208
- Physician payments**, Medicare, law freezing, 132:474–ghn
- Physician-scientists**, attrition of young, 132:477–p
- PillCam COLON capsule endoscopy**, 132:2586–agai
- PIN1**, interaction with hepatitis B X-protein, in liver cancer, 132:1088, 132:1180–e, 132:2618–c
- Pioglitazone**, for nonalcoholic steatohepatitis, 132:836–ghn
- Placebo outcome**, in ulcerative colitis, 132:516
- Plasminogen activator inhibitor 1**, in obesity, 132:2109
- Platelets**, in colitis, CD40-CD40 ligand and, 132:955
- p11 mRNA expression**, in irritable bowel syndrome, 132:1–tmig, 132:17
- PMS2 deletion**, homozygous, and colorectal cancer, 132:527
- p53-mutant hepatocellular carcinoma**, telomerase deletion in, 132:1465
- Pneumatic dilation**, for achalasia, *versus* myotomy, 132:811–ss
- Polycystic liver diseases**  
long-acting somatostatin analogs for, 132:833–tmig  
octreotide for, 132:1104
- Polyps, colorectal**  
identifying new biomarkers for, 132:823–c  
improving detection of, technology *versus* technique in, 132:1221–ccig  
PillCam COLON capsule endoscopy for, 132:2586–agai
- Porcine hepatocyte transplants**, in monkeys, 132:321, 132:450–e
- Portal hypertension**, nitrofuripropfen and (rat), 132:709
- Positron emission tomography (PET)**, 132:11–ccig  
of hypersensitivity to gastric distention, 132:1684  
quantification of liver glucose metabolism by, 132:531, 132:794–e  
whole-body, for colorectal cancer diagnosis, 132:473–ghn
- Postinfectious irritable bowel syndrome**,  
132:458–ss, 132:481–ccig, 132:1375
- PPAR $\gamma$** . *See* Peroxisome proliferator-activated receptor gamma
- Preclinical evaluation**, of cancer therapy, 132:2285–ccig
- Pregnancy**, gastrointestinal medication use in, 132:824–c
- Preterm neonates**  
esophageal peristalsis in, development of, 132:1718  
parenteral nutrition-associated cholestasis in, oral erythromycin and decrease in, 132:1726
- Primary sclerosing cholangitis (PSC)**, biliary epithelial cell antibodies in, 132:1504
- Primates**, porcine hepatocyte transplant to, 132:321, 132:450–e
- Print and Media Reviews**  
*Aging and the Gastrointestinal Tract*, 132:1196  
*Alcohol and the Gastrointestinal Tract*, 132:2076  
*Barrett’s Esophagus and Esophageal Adenocarcinoma*, 132:820  
*Challenges in Colorectal Cancer*, 132:1629  
*Challenges in Inflammatory Bowel Diseases*, 132:2075  
*Clinical Dilemmas in Inflammatory Bowel Disease*, 132:820  
*Colorectal Cancer: Evidence-Based Chemotherapy Strategies*, 132:1630  
*Considering Weight-Loss Surgery: The Facts to Know for a Healthy Recovery*, 132:462  
*Digestive Endoscopy in the Second Millennium: From the Lichtleiter to Echoendoscopy*, 132:462  
*Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management*, 132:2614  
*FEESST – Flexible Endoscopic Evaluation of Swallowing With Sensory Testing*, 132:461  
*Liver and Pancreatic Diseases Management*, 132:1196

- Living with Hepatitis C: A Survivor's Guide*, 132:2614
- Making Sense of IBS: A Physician Answers Your Questions About Irritable Bowel Syndrome*, 132:2615
- Management of Eating Disorders and Obesity*, 132:2075
- Netter's Gastroenterology*, 132:1196
- Philosophical Transactions of the Royal Society (Biological Sciences) Theme Issue "Appetite,"* 132:819
- Probiotics**  
and intestinal epithelial cell growth and survival, 132:562  
for irritable bowel syndrome, 132:813–ss
- Progenitor cell(s)**  
pancreatic, in ductal epithelium, isolation of, 132:720  
tumorigenic, in liver cancer, 132:2542
- Progenitor (stem) cell therapy**  
in inflammatory bowel disease (mice), 132:944, 132:1171–e  
in liver regeneration, 132:1077
- Progesterone**, and macrophage migration inhibitory factor, in colitis (rat), 132:982
- Progressive familial intrahepatic cholestasis (PFIC)**, resequencing chip for diagnosis of, 132:119
- Proliferating cholangiocytes**, 132:415–srr
- Prostaglandins**, in colonic stress response, 132:1791
- Prostate cancer**, obesity and related metabolic disturbances and, 132:2208
- Protease(s)**, in *Clostridium difficile* toxin A enteritis, 132:2422, 132:2599–e
- Protease-activated receptor 2 (PAR<sub>2</sub>)**, in *Clostridium difficile* toxin A enteritis, 132:2422, 132:2599–e
- Protein kinase A (PKA)**, vasoactive intestinal peptide and, 132:1212–tmig, 132:1388
- Protein kinase C $\alpha$** , in alcoholic pancreatitis, 132:1527
- Proton pump inhibitors**  
comparison of, 132:1622–ss  
and hip fracture, 132:2063–ss
- PROVE 1 trial**, 132:2282–ghn
- Pseudo-obstruction**, chronic intestinal, buserelin-induced, 132:45
- Psychological stress**, PPAR $\gamma$  and colonic response to, 132:1791
- Push enteroscopy**  
*versus* capsule, in obscure intestinal bleeding, 132:831–tmig, 132:855  
of small bowel, 132:1651–ccig
- Quantitative multiplex polymerase chain reaction of short fluorescent fragments (QMPSF)**, 132:645
- Race/ethnicity**  
and liver cancer, 132:2557–rev  
and obesity, 132:2087
- Radioprotection**, lysophosphatidic acid type 2 receptor in, 132:1834
- Rectal carcinoid tumor**, 132:853–ccig, 132:1209–ccig
- Reflux disease**. *See* Gastroesophageal reflux disease
- Reflux symptoms**, in opera choristers, 132:890
- Regional cerebral blood flow**, during gastric distention, in functional dyspepsia, 132:1684
- Regulatory T cells**, in hepatocellular carcinoma, 132:2328
- RelA/p95**, in TNF-induced hepatocyte apoptosis (mice), 132:2489, 132:2601–e
- Renin-angiotensin system (RAS)**  
in alcoholic hepatitis, 132:687  
and esophageal contractility, 132:249
- Replication checkpoint**, in colorectal cells, 5–ASA and, 132:221, 132:1635–c
- Resequencing chip**, for intrahepatic cholestasis diagnosis, 132:119
- Resistance**, drug, in chronic hepatitis B, 132:1574–rev
- Resistin**, in obesity, 132:2107
- Retinoid binding protein 4**, in obesity, 132:2108
- Reviews in Basic and Clinical Gastroenterology**  
Acute Pancreatitis: Bench to Bedside, 132:1127  
Chronic Pancreatitis: Challenges and Advances in Pathogenesis, Genetics, Diagnosis, and Therapy, 132:1557  
Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B, 132:1574  
The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies, 132:1979–rev  
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, 132:2557  
Navigating the Maze of Hepatitis B Treatments, 132:1586  
Pancreatic Development and Disease, 132:745  
The Serotonin Signaling System: From Basic Understanding to Drug Development for Functional GI Disorders, 132:397
- RhoA/ROCK**, H-*ras* inhibition of, 132:1401
- Ribavirin**, for hepatitis C  
mutagenic effect of, 132:921, 132:1757, 132:2050–e  
with peginterferon  
EASL report on, 132:2281–ghn  
for post-transplant recurrence prevention, 132:1746  
for retreatment, 132:103
- Rifabutin**, for Crohn's disease, in two-year combination therapy, 132:2313, 132:2594–e
- Rimonabant**, for obesity, 132:2239
- RNA interference (RNAi)**, application to gastrointestinal diseases, 132:2291–ccig
- RNA mutagen**, ribavirin as, in hepatitis C, 132:921, 132:1757, 132:2050–e
- RNA silencing**, application to gastrointestinal diseases, 132:2291–ccig
- Rofecoxib**, peptic ulcer and bleeding events with, 132:490
- Rosiglitazone**, for active ulcerative colitis, 132:2585–agai
- R-spondin1 (Rspo1)**, and colitis (mice), 132:1331
- Safety**, drug, FDA reinforcement of commitment to, 132:1644–ghn
- Saint**, Charles F. M., 132:476–bio
- Satiety signals**, from gut hormones, 132:2116
- SCH 503034**, with peginterferon, for nonresponders in hepatitis C, 132:1270, 132:1611–e
- Schwannoma**, benign, of pancreatic head, 132:489–clin, 132:830–clin
- Sclerosing encapsulating peritonitis**, perforative peritonitis on, in alcoholic cirrhosis, 132:854–ccig, 132:1210–ccig
- Secretions**, in cholera, lectin-based inhibitors of, 132:1234
- Secretory cells**, production of, *Math1* and, 132:2478
- Selected Summaries**  
Are All Proton Pump Inhibitors Created Equal?, 132:1622  
Biological Therapies for Pancreatic Cancer, 132:2607  
Central Control of Pancreatic Cancer Pain: Protecting the Enemy?, 132:1191  
CpG Island Methylator Phenotype: The Third Way of Colorectal Carcinogenesis, 132:1184



- How Common Is Chronic Liver Disease from Acute Drug-Induced Liver Injury?, 132:2067
- Impotent Immune System: An Underlying Problem in Crohn's Disease, 132:2609
- Interleukin-10 and Viral Clearance: Translation to Viral Hepatitis, 132:2611
- Irritable Bowel Syndrome: A Chronic Sequelae of Acute Gastroenteritis, 132:458
- Keeping Harmful Intruders at Bay: Insights into the Mechanism of Barrier Dysfunction during Inflammatory Bowel Disease, 132:454
- Large-Scale Sequencing of the Colorectal Cancer Genome Unearths Novel Pathways to Tumorigenesis and Provides Potential Druggable Targets for Cancer Therapy, 132:1186
- New Insights into a Controversial Topic: The Methylation-Cancer Connection, 132:2069
- Night Vision Goggles for Surveillance of Barrett's Esophagus: A Paradigm Shift Is Coming!, 132:1189
- Patients Prefer Conventional to Virtual Colonoscopy, 132:809
- Physical Activity and Colorectal Cancer Survival: The More METs the Better, 132:456
- Pneumatic Dilation or Myotomy for Achalasia?, 132:811
- Probiotics in Irritable Bowel Syndrome: Has the Time Arrived?, 132:813
- Proton Pump Inhibitors and Hip Fracture: Cause for Alarm?, 132:2063
- Refining Colorectal Cancer Screening Recommendations Based on Gender, 132:2605
- Role of Impedance/pH Monitoring in Refractory GERD: Let's Be Careful Out There!, 132:1621
- With Screening Colonoscopy, What You See Is What You Get, 132:2065
- Sizing Up the Association Between Body Fat and Colorectal Cancer, 132:816
- Tacrolimus for Active Ulcerative Colitis? Yes! (Even Though Cochrane Says "No"), 132:1192–ss
- Tasteless without Wingless?, 132:2071
- Therapeutic Doses of Acetaminophen Frequently Cause Elevated Amino-transferases in Healthy Volunteers: Is It Significant?, 132:1624
- Vaccine-Induced T-Cell Responses Against HCV: One Step Taken, More to Follow, 132:1626
- Selective adhesion molecule inhibitors**, for Crohn's disease, 132:1641–tmig, 132:1672
- Sensory neurons**, in irritable bowel syndrome, mast cell excitation of, 132:26
- Serotonin agonists**, 132:397–rev
- Serotonin antagonists**, 132:397–rev
- Serotonin-1A receptor gene** (*HTR1A*), as predictor of interferon-induced depression, 132:1279
- Serotonin-related proteins**, in irritable bowel syndrome, 132:1–tmig, 132:17
- Serotonin release**, from enterochromaffin cells in neonates (guinea pig), 132:2438 odorant stimulation and, 132:1643–tmig, 132:1890
- Serotonin reuptake transporter (SERT)**, 132:397–rev in irritable bowel syndrome, 132:1–tmig, 132:17, 132:437–e in neonates, expression of (guinea pig), 132:2438
- Serotonin signaling system**, 132:397–rev
- SERPINA1**, in intrahepatic cholestasis, testing for, 132:119
- Sex**. *See* Gender
- Sex steroid hormones**, and macrophage migration inhibitory factor, in colitis (rat), 132:982
- S gene mutant**, and HBsAg seroclearance in lamivudine-treated hepatitis B, 132:543
- Short-chain fatty acid (SCFA)**, and intestinal sodium absorption, 132:236
- Sibutramine**, for obesity, 132:2239
- Sigmoidoscopy**, flexible *versus* colonoscopy and FOBT, 132:2277–tmig, 132:2304, 132:2591–e in Veteran's Affairs patients, 132:4–ghn
- Silencing of RNA**, application to gastrointestinal diseases, 132:2291–ccig
- Silymarin**, for chronic hepatitis C, 132:1925
- Singers**, reflux symptoms in, 132:890
- SLC64A**, in irritable bowel syndrome, 132:17
- Small interfering RNAs (siRNAs)**, application to gastrointestinal diseases, 132:2291–ccig
- Small intestine** capillary hemangioma of, 132:1656–clin, 132:2084–clin imaging of, update on, 132:1651–ccig pacemaker activity in, mechanism and spread of, 132:1852, 132:2057–e
- Small molecule regulators**, of hepatitis C virus, screen for, 132:311
- Smoking**, and GERD risk, 132:87
- Smooth muscle cells**, excitation-transcription coupling in, vasoactive intestinal peptide and, 132:1212–tmig, 132:1388
- S-Nitrosoglutathione**, glial release of, and barrier function, 132:1344, 132:1615–e
- SOCS-3** and interferon response in chronic hepatitis C, 132:733 silencing, in cholangiocarcinoma, 132:384
- Sodium absorption**, intestinal, butyrate and, 132:236
- Sodium iodide symporter**, in cholangiocarcinoma, 132:1495
- Solid pseudopapillary tumor of pancreas**, 132:1224–clin, 132:1638–clin
- Soluble carrier protein (SLC64A)**, in irritable bowel syndrome, 132:17
- Somatic quantitative genetic alterations**, in colorectal cancer, detection of, 132:645
- Somatostatin analogs**, for polycystic liver diseases long-acting, 132:833–tmig octreotide, 132:1104
- Sp3**, in sodium channel regulation, 132:236
- Spasmolytic polypeptide-expressing metaplasia (SPeM)**, amphiregulin deficiency and (mice), 132:1804, 132:2053–e
- SPD476 (MMX mesalamine)**, for active ulcerative colitis, 132:1–tmig, 132:66
- Special Reports and Reviews** Managing Access to Liver Transplantation: Implications for Gastroenterology Practice, 132:1152 Proliferating Cholangiocytes: A Neuroendocrine Compartment in the Diseased Liver, 132:415 A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis, 132:763
- Splenic infarction**, total, due to torsion, 132:2296–clin, 132:2621–clin
- Splicing factor-1 (SF1)**, and  $\beta$ -catenin/TCF4 complex, 132:1039
- Sporadic colorectal cancer** APC inactivation in, 132:2448 CpG island methylator phenotype (CIMP) in, 132:127 as infectious disease, 132:797–e

- Squamous cells**, transformation in Barrett's esophagus, bone morphogenetic protein 4 and, 132:2412
- Src signaling**  
in colonic epithelial cell survival, 132:587  
in *Helicobacter pylori* infection, 132:1309
- STAT3**  
in cholangiocarcinoma, SOCS-3 silencing and, 132:384  
and hepcidin activation, 132:294, 132:447-e
- Steatohepatitis, nonalcoholic.** *See* Nonalcoholic steatohepatitis
- Steatosis, hepatic.** *See* Hepatosteatorosis
- Stellate cells**  
hepatic  
activation of, gene expression during, 132:1937, 132:2059-e  
Forkhead transcription factor FoxO1 and, 132:1434  
pancreatic  
apoptosis and autophagy of, tocotrienol-induced (rat), 132:2518  
in microenvironment for cancer, perostin and, 132:1213-tmig, 132:1447
- Stem cell(s)**  
pancreatic, in ductal epithelium, isolation of, 132:720  
tumorigenic, in liver cancer, 132:2542
- Stem cell therapy**  
in inflammatory bowel disease (mice), 132:944, 132:1171-e  
in liver regeneration, 132:1077
- Sterol regulatory element binding protein 1 (SREBP1)**, hepatitis B X-protein and, 132:1955
- Stress**  
colonic response to, PPAR $\gamma$  and, 132:1791  
endoplasmic response to, IL-10 and, 132:190  
oxidative  
in alcoholic hepatitis, 132:687  
in cancers of colon, prostate, and pancreas, 132:2208
- Superoxide**, *Enterococcus faecalis* production of, and chromosomal instability, 132:551
- Suppressor of cytokine signaling (SOCS)**  
and interferon response in chronic hepatitis C, 132:733  
silencing, in cholangiocarcinoma, 132:384
- survivin**, FHL2 suppression and, 132:1066
- Swallowing**, flexible endoscopic evaluation of, 132:461-pmr
- Tacrolimus**, for active ulcerative colitis, 132:1192-ss
- Taiwan**, universal hepatitis B vaccination in, impact and implications of, 132:1287
- Tapeworm**, and colitis (mice), 132:1320
- Taste bud development**, Wnt signaling in, 132:2071-ss
- Tax Relief and Health Care Act of 2006**, 132:474-ghn
- T-Bet transcription factor**, in liver injury, IL-28A and, 132:358
- T cell(s)**  
in autoimmune enteropathy, 132:1694  
CD4<sup>+</sup>NKG2D<sup>+</sup>, in Crohn's disease, 132:2346  
in celiac disease, chemokine receptor 9 and, 132:2371  
in colitis, IL-23 antibodies and IL-17 and, 132:2278-tmig, 132:2359  
colitogenic, 132:176  
CX3CR1, in inflammatory bowel disease, fractalkine recruitment of, 132:139  
FOXP3<sup>+</sup>, migration in colitis, chemokine network and, 132:966  
in *Helicobacter pylori* infection,  $\gamma$ -glutamyl transpeptidase and, 132:1642-tmig, 132:1820  
in hepatitis C  
acute, 132:654  
alcohol use and, 132:698  
chronic, 132:667, 132:801-e  
vaccine-induced responses of, 132:1626-ss  
regulatory, in hepatocellular carcinoma, 132:2328
- T-cell chemoattractant**, in inflammatory bowel disease, IL-21 enhancement of, 132:166
- T-cell factor (TCF)**  
in colorectal cancer, 132:628  
TCF-4, coactivation with  $\beta$ -catenin, splicing factor-1 and, 132:1039
- T-cell LIGHT**, disruption of epithelial barrier by, 132:2279-tmig, 132:2383
- T-cell lymphoma**, enteropathy-type, whole-genome analysis and HLA genotyping of, 132:1902
- T-cell-mediated liver injury**, IL-28A in, 132:358
- Tegaserod**  
for irritable bowel syndrome, 132:397-rev  
withdrawal from market, 132:2287-p
- Telaprevir**, for hepatitis C  
EASL report on, 132:2282-ghn  
with pegylated interferon, 132:5ghn, 132:1767, 132:2281-ghn  
resistance to, 132:1767
- Telbivudine**, for hepatitis B, 132:1586-rev
- Telomerase deletion**, in p53-mutant hepatocellular carcinoma, 132:1465
- Tetomilast**, for active ulcerative colitis, 132:76
- Thalassemia**, hepatitis C virus clearance in, 132:1634-c
- This Month in Gastroenterology**  
Another Tool in Treating Acetaminophen Liver Injury, 132:2  
Anti-IL23 Reverses an T-Cell-Driven IL-17 Induced Colitis in Mice, 132:2278  
Colonoscopy or Sigmoidoscopy and Fecal Occult Blood Testing for Colorectal Tumor Screening?, 132:2277  
Congressional Action Freeze Physician Payments, 132:474  
Congress Passes 2006 NIH Reform Act, 132:474  
Disruption of the Intestinal Epithelial Barrier Directly by T-Cell LIGHT, 132:2279  
Dual Roles of Vasoactive Intestinal Peptide in Colonic Smooth Muscle: Motor Inhibition and Transcriptional Priming for Motor Excitation, 132:1212  
Enterochromaffin Cells Pass the "Sniff" Test: Newly Found Gustatory Function Triggers Serotonin Release in the Intestine, 132:1643  
Ethanol Impairs Dendritic Cell Function and HCV NS5 Clearance in Mice, 132:471  
Expression of Serotonin-Related Proteins in Irritable Bowel Syndrome, 132:1  
High-Dose Mesalamine Preparation for the Treatment of Active Ulcerative Colitis, 132:1  
IL-23 Receptor Variations and Susceptibility for Inflammatory Bowel Disease, 132:1641  
Infliximab Therapy in Childhood Crohn's Disease, 132:831  
The Invasive Nature of *Helicobacter pylori*, 132:833  
A Less Gastrotoxic NSAID by Linkage to a Hydrogen Sulfide-Releasing Molecule, 132:2  
Long-term Outcome After Treatment of High-Grade Dysplasia in Barrett's Esophagus, 132:1211  
Long-term Outcome of Ulcerative Colitis, 132:469

- Mechanism for *Helicobacter pylori*-induced T-cell Suppression in Persistent Infection, 132:1642
- Minimally Noxious Priming of Neonatal Rat Colons for Adult Colonic Visceral Hypersensitivity Goes Through the Vanilloid 1 Receptor, 132:470
- Peptic Ulcer Complications Among Users of NSAIDs and COXIBS in the General Population, 132:469
- A Potential Role for Long-Acting Somatostatin Analogs in the Treatment of Polycystic Liver Diseases, 132:833
- Push Enteroscopy or Capsule Enteroscopy in Obscure Intestinal Bleeding, 132:831
- Risk of Morality and Elevated Serum Aminotransferases, 132:475
- Surgical Risk in Cirrhosis, 132:1211
- Who Has Incomplete Colonoscopies?, 132:2277
- T84-intestinal epithelial exosomes**, function of, 132:1866
- Tissue regeneration**, in inflammatory bowel disease, stem cell therapy for (mice), 132:944, 132:1171-e
- Tissue transglutaminase**, in celiac disease, antibodies to, 132:1245
- Tobacco smoking**, and GERD risk, 132:87
- Tocotrienols**, pancreatic stellate cell death induced by (rat), 132:2518
- Toll-like receptor 2**, barrier function regulation by, 132:1359
- Toll-like receptor 4**, polymorphism, and gastric cancer, 132:905
- in primary sclerosing cholangitis, 132:1504
- Toll-like receptor 9**, in primary sclerosing cholangitis, 132:1504
- Toxin A-induced enteritis**, PAR<sub>2</sub>, DPPI, trypsin, and trypsins in, 132:2422, 132:2599-e
- TRA-8 anti-death receptor-5 mAb**, for pancreatic cancer, 132:2607-ss
- Transcription factors**, activation in *Helicobacter pylori* infection (gerbils), 132:1024
- Transferrin receptor 2 (TfR2)**, disruption, in iron overload (mice), 132:301
- Transforming growth factor- $\beta$  (TGF- $\beta$ )**, in celiac disease, inhibition by IL-15, 132:994, 132:1174-e
- in hepatitis delta virus, antigen modulation of, 132:343
- Transforming growth factor- $\beta$  RII (TGF- $\beta$ RII)**, in *Elf-3* deficiency, rescue by (mice), 132:1410
- Transglutaminase**, TG2, and Mallory body inclusions, 132:1515
- tissue (TTG), in celiac disease, antibodies to, 132:1245
- Transient lower esophageal sphincter relaxation**, obesity and, 132:883
- Transient receptor potential vanilloid 1 (TRPV1)**, in visceral hypersensitivity (rat), 132:470-tmig, 132:615
- Transit**, in large bowel, enteric occult reflex and, 132:1912
- Translational research**, 132:8-ccig
- Treg (regulatory T cells)**, in hepatocellular carcinoma, 132:2328
- Triglycerides**, adipose differentiation-related protein and, 132:1947
- in nonalcoholic fatty liver disease, 132:2191
- obesity and, 132:2181
- Trypsins**, in *Clostridium difficile* toxin A enteritis, 132:2422, 132:2599-e
- Tryptase**, in *Clostridium difficile* toxin A enteritis, 132:2422, 132:2599-e
- TUCAN**, in inflammatory bowel disease, lack of association found, 132:2078-c, 132:2080-c
- Tumor cell resistance**, in colorectal cancer, *XAF1* and, 132:2459
- Tumor necrosis factor (TNF)**, in Crohn's disease, adalimumab and, 132:52, 132:1644-ghn
- in hepatitis C, Silymarin and, 132:1925
- hepatocyte apoptosis induced by, RelA/p65 and (mice), 132:2489, 132:2601-e
- Twin studies**, of lifestyle factors and risk for GERD, 132:87
- UGT2B7 genotype**, and diclofenac hepatotoxicity, 132:272
- Ulcer(s)**, COXIBS and, 132:469, 132:490
- NSAIDs and, 132:469
- rofecoxib and, 132:490
- time trends in mortality, 132:2320
- Ulcerative colitis**, active
- MMX mesalamine for, 132:1-tmig, 132:66
- placebo outcome in, 132:516
- rosiglitazone for, 132:2585-agai
- tacrolimus for, 132:1192-ss
- tetomilast for, 132:76
- chromoscopy-guided endomicroscopy in, 132:874
- clinical trials in, activity indices and efficacy end points for, 132:763-srr
- colectomy rate in, European, 132:507
- genome-wide association studies of, 132:2045-e
- IL-23 receptor gene in, 132:1641-tmig, 132:1657, 132:2045-e
- long-term outcome of, 132:469-tmig
- neoplasias with, CpG island methylator phenotype and, 132:1254
- TUCAN/CARD8* in, lack of association found, 132:2078-c, 132:2080-c
- Ultrasound**, 132:11-ccig
- endoscopic, of pancreas, 132:484-ccig
- U. S. Multi-Society Task Force on Colorectal Cancer**, 132:2277-tmig, 132:2297, 132:2588-e
- Universal vaccination**, hepatitis B, in Taiwan, impact and implications of, 132:1287
- Upper gastrointestinal complications (UGICs)**, of NSAIDs and COXIBS, 132:469-tmig, 132:498
- Urgency**, in irritable bowel syndrome, 132:38
- Vaccination**, hepatitis C, T-cell responses to, 132:1626-ss
- universal hepatitis B, in Taiwan, impact and implications of, 132:1287
- Vacuolating cytotoxin A (VacA)**, in *Helicobacter pylori* infection, 132:1642-tmig
- Vanilloid 1 receptor**, in visceral hypersensitivity, 132:470-tmig, 132:615
- Vasoactive intestinal peptide (VIP)**, induction of excitation-transcription coupling in smooth muscle cells by, 132:1212-tmig, 132:1388
- Veteran's Affairs patients**, colorectal cancer screening in, 132:4-ghn
- Virtual colonoscopy**, *versus* conventional, 132:809-ss
- Visceral adipose-tissue-derived serine protease inhibitor**, 132:2108
- Visceral hypersensitivity**, to gastric distention, in functional dyspepsia, 132:1684

- in irritable bowel syndrome
  - normalization of, 132:464–c
  - postinfective, brain-gut axis alterations and, 132:1375
  - vanilloid 1 receptor in, 132:470–tmig, 132:615
- Visceral-nociceptive sensory neurons**, in irritable bowel syndrome, mast cell excitation of, 132:26
- Viscerotopic organization of gut**, 132:1546, 132:1618–e
- Visfatin**, in obesity, 132:2108
- Vitamin B<sub>6</sub> intake**, and pancreatic cancer risk, 132:113
- Vomiting**, serotonin antagonists for, 132:397–rev
- Von Hippel-Lindau disease type I**, 132:16–clin, 132:468–clin
- Wales**, survival from malignant digestive endocrine tumors in, 132:899
- Weight loss**
  - drug treatment for, 132:2239
  - lifestyle modification for, 132:2226
  - surgery for, 132:462–pmr, 132:2253
- Whipple, Allen Oldfather**, 132:1654–bio
- White light endoscopy (WLE)**, of Barrett's esophagus, 132:1189–ss
- Whole-body cross-sectional imaging**, 132:11–ccig
- Whole-body scans**, for colorectal cancer diagnosis, 132:473–ghn
- Wilson's disease**, late-onset, 132:1294
- Wingless**. *See* Wnt signaling system
- Wnt signaling system**
  - in colorectal cancer, 132:208, 132:628
  - splicing factor-1 and, 132:1039
  - in taste bud development, 132:2071–ss
- Women**, advancement in gastroenterology by, 132:1598–agai
- Xenotransplantation**, of hepatocytes, 132:321, 132:450–e
- X-linked inhibitor of apoptosis protein-associated factor 1 (XAF1)**, in colorectal cancer, 132:2459
- Young physician-scientists**, attrition of, 132:477–p